

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



19 JAN 2005



(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007034 A1

- (51) International Patent Classification⁷: **A61F 2/04**, 2/06, 2/24, C08F 283/04
- (21) International Application Number: PCT/US2004/021831
- (22) International Filing Date: 8 July 2004 (08.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/485,486 8 July 2003 (08.07.2003) US
- (71) Applicant (for all designated States except US): **THE CHILDREN'S HOSPITAL OF PHILADELPHIA** [US/US]; 34th Street and Civic Center Boulevard, Philadelphia, PA 19104 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LEVY, Robert, J.** [US/US]; 440 Merion Road, Merion Station, PA 19066 (US). **ALFERIEV, Ivan** [RU/US]; 1341 Blackwood Clementon Road, #963, Clementon, NJ 08021 (US). **STACHELEK, Stanley, J.** [US/US]; 518 Queen Street, Philadelphia, PA 19147 (US).
- (74) Agent: **VOLIN, Marina, E.**; Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., Seven Penn Center, 1635 Market Street, 11th Floor, Philadelphia, PA 19103 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STEROID LIPID-MODIFIED POLYURETHANE AS AN IMPLANTABLE BIOMATERIAL, THE PREPARATION AND USES THEREOF

(57) Abstract: A modified polyurethane including a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane, methods of preparing modified polyurethanes and the use thereof as an implantable biomaterial. Figure 2 shows the steps for making polyurethane having cholesterol pendent from a urethane nitrogen.

WO 2005/007034 A1

BEST AVAILABLE COPY

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefit of provisional Application No. 60/485,486 filed July 8, 2003, which is incorporated herein in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

10 This research was supported in part by U.S. Government funds (National Heart, Lung and Blood Institute grant number HL 59730), and the U.S. Government may therefore have certain rights in the invention.

SPECIFICATION

BACKGROUND OF THE INVENTION

1. FIELD OF INVENTION

15 This invention relates to polyurethanes modified to retain epithelial cells. Particularly, it relates to implants made from such polyurethanes. . . .

2. DESCRIPTION OF RELATED ART

20 Polyurethanes, i.e. polymers which comprise repeating units having a urethane group in the polymer backbone, can be used to form bulk polymers, coatings, fillings, and films. Notably, polyurethanes are also readily machinable once set. These properties of polyurethanes have rendered them useful for medical and non-medical purposes.

25 With regard to medical applications, polyurethanes are widely used in implants, particularly cardiovascular implants, as highly biocompatible biomaterials. For example, polyurethanes have been employed in the manufacture of pacemaker electrodes, vascular grafts, and artificial heart valves.

30 Medical uses of polyurethanes have, however, been heretofore limited by, among other reasons, the tendency of polyurethane products which contact the blood stream or other biological fluids to calcify, induce thrombogenesis, and/or impede cellular attachment and growth. Promotion of cell adhesion on medical devices comprising polyurethane is of particular concern, as the establishment of a confluent monolayer of endothelial cells is critical for neovascularization (Simionescu, N. and N. Simionescu, eds. Endothelial Cell Dysfunctions. 1992. New York:Plenum Press). Additionally, the cellular attachment to vascular grafts or
35 implants must be strong enough to withstand the fluid shear stress exerted by blood and other biological fluids. Modified polyurethane surfaces currently available, such as those that have been deliberately textured or cast as foams, have provided for only disorganized cell growth.

WO 2005/007034 PCT/US2004/021831
Polyurethane surfaces have also been coated with fibronectin and collagen which are potent ligands for cell surface receptors. Despite promoting cell adhesion, fibronectin and collagen coated polyurethanes are not ideal modifications because apoptosis and calcification of vascular cells has been observed when cultivated on collagen coated matrices and vascular cells seeded on fibronectin coated polyurethane failed to thrive.

As those skilled in the art will appreciate, a need exists for implantable devices comprising polyurethane which allows for enhanced cellular attachment and growth.

Natural blood contact surfaces, such as those found within blood vessels, possess mechanisms that prevent blood from clotting during normal passage along the surface. In the case of a mammalian artery, the immediate blood contact surface comprises a layer of non-thrombogenic ECs. Immediately external to the EC layer is the remainder of the intima: a subendothelial matrix layer of basement membrane and underlying glycoprotein-bearing extracellular matrix, and the internal elastic lamina. Surrounding the intima layer is the multilaminate media structure containing smooth muscle cells (SMCs) and elastin, and surrounding this media is the adventitia, the most external layer comprised of fibroblasts and connective tissue. Both the subendothelial layer and media are generally considered to be thrombogenic in nature in order to maintain hemostasis when the vascular system is injured.

Intact endothelial linings are considered to be non-thrombogenic unless damaged. Because of their blood-contacting location, ECs have been thoroughly investigated with respect to their anti-thrombogenic function. ECs are known to synthesize or bind a number of substances with coagulation-inhibiting or fibrinolytic function including heparan sulfate/antithrombin III, dermatan sulfate/heparin cofactor II, thrombomodulin/protein C/protein S, prostacyclin and tissue-type plasminogen activator. Furthermore, segments of endothelium-bearing autologous vessel transplanted from one site to another in an individual to bypass diseased vessels exhibit an incidence of thrombosis substantially less than that of synthetics used in the same application. For these reasons, it has been assumed that ECs are responsible for the non-thrombogenic activity of vessels. According to this assumption, synthetic blood contact devices capable of thrombo-resistance similar to the native vasculature would require a blood contact surface of ECs.

Numerous attempts have been made to provide prosthetic surfaces, and specifically vascular grafts, that include or develop an EC lining as described in U.S. Patent No. 5,879,383 to Bruchman et al. The overwhelming majority of these attempts have been carried out as an intraoperative cell-seeding procedure. Intraoperative cell-seeding typically involves harvesting ECs from the recipient during the procedure and immediately seeding these collected cells onto a vascular graft that has been pretreated with a substrate to enhance EC attachment. Substrates

WO 2005/007034, PCT/US2004/021831 or frequently applied to the synthetic surface include preclotted blood tubes. Extracellular matrix proteins such as fibronectin, collagen, or laminin, either singly or in combination. This approach was first reported by M. B. Herring et al. in "A single staged technique for seeding vascular grafts with autogenous endothelium," Surgery 84:498-504 (1978). In this procedure, autologous cells were seeded onto a preclotted DACRON™ graft. These seeded grafts demonstrated a decreased thrombus formation compared to control grafts without ECs. In spite of the improved initial adherence of the cells to the synthetic surface afforded through the use of these various substrata, the shear forces resulting from blood flow nevertheless leads to the loss of a substantial fraction of the applied cells.

In a variation of the above, U.S. Pat. No. 4,960,423 to Smith describes the use of elastin-derived peptides to enhance EC attachment. Some studies have used combinations of extracellular matrix molecules and cells to provide a substrate for EC attachment and growth. For example, U.S. Pat. Nos. 4,539,716 and 4,546,500 to Bell describe means by which ECs are grown on a living smooth muscle cell-collagen lattice. In addition, U.S. Pat. No. 4,883,755 to Carabasi et al. describes a technical method for seeding ECs onto damaged blood vessel surfaces.

Alternative means of growing ECs on vascular grafts have also been reported. For example, the use of physical force to apply ECs to graft surfaces is described in U.S. Pat. No. 5,037,378 to Muller et al. In another example, U.S. Pat. No. 4,804,382 to Turina and Bittman describe the application of ECs to a semi-permeable membrane in which the pores are filled with aqueous gels to allow EC coverage.

Another approach has been the seeding of ECs onto biologically-derived surfaces, including pericardium, cardiac valve leaflets, amnion, and arteries. These efforts appear to have originated with J. Hoch et al. in "In vitro endothelialization of an aldehyde-stabilized native vessel," J. Surg. Res. 44:545-554 (1988), where the authors attempted to grow endothelium on ficin-digested, dialdehyde stabilized, bovine artery. Human venous ECs were found to adhere to and spread on the remnant collagen surface of these enzyme-digested grafts, but no implant studies were performed. J. Hoch et al. also investigated the growth of endothelium on human amnion, on live, mechanically-scraped human artery, and again on ficin-digested, tanned bovine artery. (J. Hoch et al., "Endothelial cell interactions with native surfaces," Ann. Vasc. Surg. 2:153-159 (1989)). Although EC adhesion was observed on these surfaces by 2 hours, the longterm persistence of ECs on these surfaces was not examined, and, as in the previous study, none of these endothelialized materials were implanted as vascular substitutes. Schneider et al. showed that ECs could be successfully seeded onto the remaining collagenous surface of baboon vessels from which the intima was removed. (P. A. Schneider et al., "Confluent durable endothelialization of endarterectomized baboon aorta by early attachment of cultured endothelial

Two 2005/007034 Surg. 55372 (1990)). Lalka et al. used dete PCT/US2004/021831 line arteries to produce an ethanol-fixed acellular vascular matrix onto which human umbilical vein ECs were successfully seeded in vitro. (S. G. Lalka et al., "Acellular vascular matrix: A natural endothelial cell substrate," Ann. Vasc. Surg. 2:108-117 (1989)).

5 Although a small number of grafts seeded lumenally with ECs have been implanted clinically outside of the United States, and improved patencies over non-seeded grafts have been observed, this approach has generally enjoyed mixed success, and the concept still faces many challenges as described in U.S. Patent No. 6,733,747 to Anderson et al. First, it is necessary that the cells used to seed the graft be autologous or otherwise non-immunogenic to avoid
10 recognition and destruction of the cells by the patient's immune system. To obtain autologous ECs from a patient, the cells must be harvested from an isolated blood vessel. The harvesting surgical procedure not only increases prosthetic implant preparation time, but can also lead to complications and discomfort for the patient.

Second, retention of the cells on the graft surface after implantation has been an issue. A
15 number of methods have been disclosed to address this issue, and include forcible injection of ECs into the graft, preclotting and seeding the luminal surface of the graft, static adhesion-seeding of the lumen, vacuum seeding of the lumen, seeding the lumen in an extracellular matrix, and seeding of the lumen using electrostatic and gravitational forces. These methods are reviewed or disclosed in more detail in U.S. Patent No. 5,723,324 to Bowlin et al.

20 Additionally, it has been suggested that flow conditioning the seeded graft in vitro prior to implantation would improve cell retention by allowing the cells to secrete adhesion factors in response to slowly increasing shear rates (Dardik et al., 1999, J Vasc Surg 29: 157-67; Ballerman et al., 1995, Blood Purif 13: 125-34; and Ott and Ballerman, 1995, Surgery 117: 334-9). Although there is some evidence that methods such as conditioning may improve cell
25 retention, all of these methods add yet another level of complexity to the seeding process and it is still not clear that significantly improved cellular retention can be achieved.

Thus, there remains a need in the art for a better EC seeding technique of prostheses in order to provide long-term patency and eventual healing by inhibiting thrombosis and inflammatory cell interactions. The instant invention provides a novel method of EC seeding by
30 utilizing a cholesterol modified polyurethane surface to which the ECs can attach.

All references cited herein are incorporated herein by reference in their entireties.

BRIEF SUMMARY OF THE INVENTION


The invention is aimed at utilizing endothelial seeding of polyurethane heart valve cusps as a cell therapy approach for inhibiting thrombosis and inflammatory cell interactions. The
35 inventors have discovered that cholesterol modification results in a polyurethane surface with membrane-lipid like properties that would facilitate cellular adhesion, thereby permitting robust

* WO 2005/007034 ~~seedling of polyurethane surfaces~~ The rationale for ~~USPTO/US2004/021831~~ ~~as~~
based on several considerations including cholesterol's resistance to enzymatic degradation, and
cholesterol's hydrophobicity, which could hypothetically facilitate strong associations between
cholesterol modified polyurethane and cellular plasma membranes ⁶. Accordingly, the invention
5 provides modified polyurethane comprising a lipid substituent pendant from at least one
urethane nitrogen and/or at least one carbon atom of the modified polyurethane.

In certain embodiments, the lipid substituent is a steroid lipid substituent. In certain
embodiments, the steroid lipid substituent is a member selected from the group consisting of a
thiol-modified cholesterol substituent, an amino-modified cholesterol substituent, a
10 carboxy-modified cholesterol substituent, and an epoxy-modified cholesterol substituent. In
certain embodiments, the thiol-modified cholesterol substituent is a
3-mercapto-2-hydroxypropyl-cholesterol.

In certain embodiments, the modified polyurethane further comprises a linker moiety
between (1) the steroid lipid substituent and (2) the at least one urethane nitrogen and/or the at
15 least one carbon atom of the modified polyurethane, wherein the linker moiety covalently binds
the steroid lipid substituent with the at least one urethane nitrogen and/or the at least one carbon
atom. In certain embodiments, the linker moiety is an (n+1)-valent organic radical comprising
at least one carbon atom. In certain embodiments, the linker moiety is a bivalent organic radical
selected from the group consisting of C₁ to C₁₈ alkylene, C₁ to C₁₈ alkyleneamino, C₁ to C₁₈
20 alkyleneoxy, C₁ to C₁₈ haloalkylene, C₂ to C₁₈ alkenylene, C₆ to C₁₈ arylene, a modified C₂ to C₁₈
alkenylene having at least one carbon substituted by a halogen group, C₂ to C₁₈ alkenylene
having one or more O, S, or N atoms incorporated into an alkenylene chain, a bivalent
heterocyclic radical, and mixtures thereof. Preferably, the linker moiety is C₁ to C₆ alkylene.
More preferably, the linker moiety is butylene.

25 In certain embodiments, the lipid substituent is a thiol-modified cholesterol substituent
bound to the at least one urethane nitrogen and wherein said modified polyurethane has a
formula:




In certain embodiments, the lipid substituent is pendant from about 0.5 to about 50% of urethane nitrogen atoms and/or about 0.5 to about 50% of carbon atoms.

In certain embodiments, the lipid substituent is pendant from 1 to 20% of urethane nitrogen atoms and/or 1 to 20% of carbon atoms. In certain embodiments, the lipid substituent is pendant from 5 to 10% of urethane nitrogen atoms and/or 5 to 10% of carbon atoms. In certain embodiments, the modified polyurethane comprises at least about 10 micromoles of the lipid substituent per gram of the modified polyurethane.

In certain embodiments, the modified polyurethane has at least two different lipid substituents pendant from urethane nitrogen atoms and/or carbon atoms.


Advantageously, said modified polyurethane is less prone to degradative oxidation than a polyurethane.

Also provided is a process for preparing the modified polyurethane of the invention, the process comprising: providing a polyurethane comprising a urethane amino moiety and at least one carbon; providing a multifunctional linker reagent of a formula:



wherein n is an integer from 1 to 3, FG is a functional group selected from the group consisting of a halogen, a carboxyl group, a sulfonate ester, and an epoxy group, LG is a leaving group selected from the group consisting of a halogen, a carboxyl group, a sulfonate ester, and an epoxy group, and R_L is an $(n+1)$ -valent organic radical comprising at least one carbon atom; providing a lipid comprising the lipid substituent;

reacting the multifunctional linker reagent with the urethane amino moiety to form a polyurethane substituted with at least one substituent group of a formula



reacting the lipid and the polyurethane substituted with the at least one substituent group to form the modified polyurethane.

WO 2005/007034 A1
In certain embodiments, R_L is a bivalent organic radical consisting of C_1 to C_{18} alkylene, C_1 to C_{18} alkyleneamino, C_1 to C_{18} alkyleneoxy, C_1 to C_{18} haloalkylene, C_2 to C_{18} alkenylene, C_6 to C_{18} arylene, a modified C_2 to C_{18} alkenylene having at least one carbon substituted by a halogen group, C_2 to C_{18} alkenylene having one or more O, S, or N atoms incorporated into an alkenylene chain, a bivalent heterocyclic radical, and mixtures thereof.

In certain embodiments, the multifunctional linker reagent is a member selected from the group consisting of a dibromoalkyl compound, a bromo-carboxyalkyl compound, and a bromo-epoxyalkyl compound.

In certain embodiments, the lipid comprises a steroid lipid and the lipid substituent comprises a steroid lipid substituent.

In certain embodiments, the steroid lipid comprises modified cholesterol and the steroid lipid substituent is a member selected from the group consisting of a thiol-modified cholesterol substituent, an amino-modified cholesterol substituent, a carboxy-modified cholesterol substituent, and an epoxy-modified cholesterol substituent.

In certain embodiments, the modified cholesterol comprises 3-mercapto-2-hydroxypropyl-cholesterol.

Also provided is a method comprising preparing the modified cholesterol by contacting a cholesterol with at least one reactant to provide the modified cholesterol having at least one substituent group, wherein the substituent group is a member selected from the group consisting of a thiol group, an amino group, a carboxy group, and an epoxy group.

In certain embodiments of the method, the cholesterol is treated with epihalohydrin to yield a glycidyl modified cholesterol and the glycidyl modified cholesterol is treated with a thiolating agent to yield a thiol modified cholesterol.

Also provided is process for preparing the modified polyurethane of the invention, the process comprising: reacting a steroid lipid with epihalohydrin to yield a glycidyl derivative of the steroid lipid; reacting the glycidyl derivative of the steroid lipid with a thiolating agent, thereby effecting opening of the glycidyl oxirane group and adding to said lipid molecule a thiol moiety having a protective group bound thereto; removing said protecting group to produce a thiol-substituted steroid lipid; reacting a polyurethane with a bi-functional linker comprising a thiol-reactive group, to yield an intermediate polyurethane having a thiol-reactive functional group wherein the thiol-reactive functional group is substituted on said urethane group nitrogen; reacting the thiol-substituted steroid lipid with the intermediate polyurethane having a thiol-reactive functional group to yield the modified polyurethane. In certain embodiments, the epihalohydrin is epibromohydrin.

In certain embodiments, the thiolating agent is selected from the group consisting of

WO 2005/007034, urea, n-butylmercaptanes, tert-butylmercaptanes, thiocyanate, and thioalkanoic acids having 2 - 6 carbon atoms.

In certain embodiments, the thiolating agent is thioacetic acid.

In certain embodiments, the bi-functional linker is a dihaloalkane having 1-12 carbon atoms.

In certain embodiments, the bi-functional linker is 1,4-dibromobutane.

Also provided is a process of producing an implant, said process comprising: providing the modified polyurethane of the invention; forming an article from the modified polyurethane; contacting the article with cells to attach the cells to the lipid substituent and thereby attach the cells to the article to form the implant, provided that a substantial portion of the cells remains attached to the implant when exposed to a fluid-induced shear stress.

In certain embodiments of the process, the lipid substituent is a member selected from the group consisting of a thiol-modified cholesterol substituent, an amino-modified cholesterol substituent, a carboxy-modified cholesterol substituent, and an epoxy-modified cholesterol substituent.

In certain embodiments of the process, the cells are endothelial cells or precursors of endothelial cells.

In certain embodiments of the process, the endothelial cells are bovine arterial endothelial cells or blood outgrowth endothelial cells.

Also provided is an implant produced by the process as described above. The non limiting examples of implant are an artificial heart; cardiac pacer leads; automatic implantable cardio defibrillator leads; a prosthetic heart valve; a cardiopulmonary bypass membrane; a ventricular assist device; an annuloplasty ring; a dermal graft; a vascular graft; a vascular stent; cardiovascular stent; a structural stent; a catheter; a guide wire; a vascular shunt; cardiovascular shunt; a dura mater graft; a cartilage graft; a cartilage implant; a pericardium graft; a ligament prosthesis; a tendon prosthesis; a urinary bladder prosthesis; a pledget; a suture; a permanently in-dwelling percutaneous device; an artificial joint; an artificial limb; a bionic construct; and a surgical patch.

Preferably in the implant, the cells are blood outgrowth endothelial cells.

Further provided is a method of treating a patient comprising providing the implant of the invention comprising modified polyurethane, wherein the implant is seeded with blood outgrowth endothelial cells.

Further provided is a method of treating or preventing a condition in a patient, said method comprising implanting in the patient an implant coated with cells, such that the cells are administered to the patient to treat or prevent the condition, wherein the cells are releasably attached to the implant by a lipid substituent pendant from at least one urethane nitrogen and/or

WO 2005/007034 at least one carbon atom of a polyurethane component of the implant. PCT/US2004/021831
condition are thrombosis and inflammatory cell interactions.

BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS

The invention will be described in conjunction with the following drawings in which like
5 reference numerals designate like elements and wherein:

Figure 1 is a reaction scheme for modification of cholesterol with a thiol-containing
substituent group by sequential reaction with epihalohydrin, thioacetic acid and hydroxylamine.

Figure 2 is a reaction scheme for the preparation of a cholesterol-modified polyurethane
from a polyurethane having a thiol-reactive functional group and a thiol-substituted cholesterol.

10 Figure 3 is a graphic representation of the number of cells attached to tissue culture
treated polystyrene, polyurethane, or cholesterol modified polyurethane (PU + Chol) per field, at
20X magnification, as a function of time.

Figure 4A are Figure 4B are photomicrographs of cholesterol modified polyurethane
heart valve leaflets seeded with endothelial precursor cells before implantation and after 30 days
15 after implantation. Figure 4C is a photomicrographs of a native heart valve before implantation,
which was used for comparison. Figure 4D is a photomicrograph of unseeded cholesterol
modified polyurethane heart valve leaflet (control) after 30 days.

Figures 5A and 5B are graphical representations of the kinetics of bovine arterial
endothelial cells (BAEC) attachment over a 45 minute time period to tissue culture treated
20 plastic (closed circles), unmodified polyurethane (open circles) and cholesterol modified
polyurethane (closed triangle) in both serum free (Figures 5A) and serum containing media
(Figures 5B). Results (mean \pm standard error) show significantly more endothelial cell
attachment over time to the cholesterol modified polyurethane surface compared to either tissue
culture treated plastic or unmodified polyurethane. Cell attachment was not dependent on serum
25 conditions. * Indicates significant difference between cell attachment on cholesterol modified
polyurethane and unmodified polyurethane ($p = 0.006$) in growth media conditions. **
Indicates values are significantly different ($p = 0.0002$) between cell attachment on cholesterol
modified polyurethane and unmodified polyurethane in serum deficient conditions.

Figure 6 is a graphical representation of the degree of bovine arterial endothelial cell
30 attachment to several different matrices (glass = tissue culture treated glass; PU = polyurethane
coated glass; PU/Chol = cholesterol modified polyurethane coated glass) at various time points
in the presence of a laminar flow of media at 25 dynes/cm².

Figure 7 is a reaction scheme for the preparation of a cholesterol-modified polyurethane
from a carboxylated polyurethane and an amino-substituted cholesterol through the use of N-
35 hydroxysuccinimide esterification. Y is a linker moiety as described further herein.

WO 2005/007034 is a schematic depicting a synthesis of a PCT/US2004/021831 air extenders which are pre-modified with reactive bromoalkyl groups. Polyurethane precursors terminated with isocyanate groups are reacted with bromoalkyl-containing diols as chain extenders. In this reaction, modification of carbon atoms of the backbone of polyurethane and not urethane nitrogen is obtained. Next, the pendant bromoalkyl groups can be used for further derivatization with, for example thiolated cholesterol as shown in Figure 2 thus resulting in modification of carbon atoms of the backbone.

Figure 9 (I II III) is a ¹H NMR spectrum confirming covalent attachment of cholesterol to a polyether urethane. The urethane fragment of Tecothane[®] was bromobutylated and then reacted with the above mentioned thiolated cholesterol as shown in Figures 1 and 2. H NMR spectrum of non-modified Tecothane[®] is shown for reference (I). Signals of pendant bromobutyl groups are clearly noticeable in the NMR spectrum (II). After covalent attachment of cholesterol, new NMR signals appear in the spectrum of the polymer as indicated (III). Alkylation of urethane nitrogens also cause pronounced changes in the region of aromatic protons (see II and III, $\delta = 7.1 - 7.5$ ppm).

Figure 10 shows Fourier Transform Infrared Spectra (FTIR) for air exposed sides of unmodified Tecothane[®] (I) and cholesterol derivatized modified Tecothane[®] (II). Results demonstrating peak shifts largely corresponding to changes in the nitrogen groups of the urethane hard segment.

Figures 11A and 11B are graphic presentations of dynamic mechanical analysis showing representative runs, wherein Figure 11 A indicates the storage modulus (Pa= Pascal's) and the Figure 11B indicates the Tan delta measurements of unmodified and cholesterol modified Tecothane. As shown in Figure 11A, at temperatures at or below the glass transition phase (T_g), the storage modulus was greater for cholesterol modified polyurethane. As shown in Figure 11A, the unmodified polyurethane had a lower T_g and a higher melting temperature (T_m) compared to the cholesterol modified polyurethane. At 37°C both storage modulus and Tan delta were similar for both polyurethane configurations.

Figure 12A and Figure 12B are 3-dimensional and 2-dimensional (inset) atomic force microscopic images and corresponding surface measurements of unmodified polyurethane (Figure 12A) and cholesterol modified polyurethane (Figure 12B). Air exposed surfaces subjected to solvent evaporation are shown. The unmodified polyurethane (Figure 12A) shows an irregular surface with grooves (indicated by arrows). In contrast the cholesterol modified polyurethane (Figure 12A) shows a smoother surface with less pronounced irregularities.

Figures 13A- L demonstrate phase microscopy of bovine arterial endothelial cells (BAEC's) growing on glass (Figs. A-D), cholesterol modified polyurethane (Figs. E-H), or unmodified polyurethane (Figs. I-L) exposed to shear flow (25 dynes/cm²) for 0 hours (Figs.

WO 2005/007034, 0.5 hours (Figs. H, F, and J), 1 hour (Figs C, G, and K), or 2 (Figs L, I, and L) hours. Magnification was 200X.

Figure 13M is a graphical representation of BAEC retention after the indicated amount of time exposed to 25 dynes/cm². After 1 hour exposure to shear, unmodified polyurethane surfaces retained significantly fewer BAEC's than the cholesterol modified polyurethane or glass substrates. After 2 hours BAEC's cultured on glass or cholesterol modified polyurethane retain 80 and 90 % of BAEC's respectively and largely retain their characteristic cobblestone appearance (Fig. D vs. Figs. H and L). In contrast almost half of BAEC's cultured on unmodified polyurethane are not retained after 2 hours. Data are mean \pm SEM. *₁p= 0.0001; *₂p=0.002; †₁p= 0.001; †₂p = 0.007.

Figures 14A - L demonstrate phase microscopy of ovine blood outgrowth endothelial cells (BOEC's) growing on glass (Figs. A, B, C, and D), cholesterol modified Tecothane (Figs. E-H), or unmodified Tecothane (Figs. I- L), and exposed to shear flow (25 dynes/cm²) for 0 (Figs. A, E, I), 0.5 (Figs. B, F, J), 1 (Figs. C, G, K), and 2 (Figs. D, H, L) hours. Magnification = 200X.

Figure 14M is a graphical representation of BOEC retention after the indicated amount of time exposed to 25 dynes/cm². After 2 hours BOEC's cultured on glass or cholesterol modified polyurethane retained 84.2 \pm 1.1 % and 90.30 \pm 3.25% of cells respectively and largely retain their characteristic cobblestone appearance (Figs. D and H vs. Fig. L). In contrast only 4.56 \pm .85% of BOEC's seeded on unmodified polyurethane were retained after 2 hours. Data are mean \pm SEM. *₁p= 0.04; *₂p=0.01; *₃p= 0.001; †₁p= 0.006; †₂p = 0.01; †₃p=0.001

Figure 15 is FTIP spectra demonstrating examples of the 1173 peak change that occurs during oxidation and is reduced by cholesterol modification of polyurethane..

Figure 16 is a block diagram showing oxidative degradation of unmodified polyurethane (a black block) and cholesterol-modified polyurethane (a white block).

Figures 17A and B demonstrate high shear (2 hour at 25 dyne/cm²) adhesion on cholesterol modified but not on unmodified with endothelial precursor cells (BOEC), wherein Fig. 17 A is a block diagram and Fig. 17B is a micrograph. (Tec is unmodified polyurethane, glass and Chol-tec is modified polyurethane).

Figs. 18 A and B, demonstrate a higher shear adhesion on cholesterol modified but not on unmodified with endothelial precursor cells (BOEC), used such as 75 dynes/cm² for 2 hours, which is significant since it is typical heart valve level shear force. Also shown are the first results we have demonstrating retention of seeded endothelial cells on cholesterol modified polyurethane in blood stream implants.

DETAILED DESCRIPTION OF THE INVENTION

lipid substituents pendant from at least one nitrogen and/or at least one carbon atom of the polyurethane and methods of making such polyurethanes. The inventors have discovered that lipid-modified polyurethane and especially steroid lipid -modified polyurethane allows for adhesion of cells which remain associated with the modified polyurethane during exposure to high shear force. Unexpectedly, the inventors have discovered that modified polyurethane is less prone to degradative oxidation than a polyurethane. Accordingly, the invention provides modified polyurethane comprising a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane.

Endothelialization of synthetic surfaces has been challenging with limited success thus far. The inventors discovered that covalent attachment of cholesterol to polyurethane via the urethane nitrogen groups would create a high affinity surface for attachment and adhesion of endothelial cells. Cholesterol was covalently bound to the polyether polyurethane, Tecothane®, by first derivatizing the polyurethane nitrogen groups with bromo-alkyl side chains, followed by reacting mercapto-cholesterol to the bromoalkyl sites. Cholesterol modified polyurethane demonstrated a qualitatively smoother surface per atomic force microscopy than nonmodified and increased surface energy (contact angle measurements) compared to unmodified polyurethane. Cell attachment assays showed a significantly higher rate of attachment of bovine arterial endothelial cells (BAEC's) ($p=0.0003$) after 45 minutes of seeding on cholesterol modified polyurethane versus unmodified polyurethane. BAEC's cultivated on cholesterol-modified Tecothane® showed significantly greater levels of cell retention compared to unmodified Tecothane® when exposed to arterial level shear stress for 2 hours (25 dynes/cm^2) with $90.0 \pm 6.23\%$ cells remaining adherent compared to unmodified polyurethane, $41.4 \pm 11.7\%$, $p = 0.0070$. Furthermore, ovine endothelial precursors, obtained as blood outgrowth endothelial cells (BOEC's), were seeded on cholesterol modified polyurethane and exposed to 25 dynes/cm^2 shear conditions for 2 hours, with the retention of $90.30 \pm 3.25\%$ of seeded cells versus unmodified polyurethane, that retained only $4.56 \pm 0.85\%$ ($p<0.001$). It is concluded that covalently linking cholesterol to polyurethane results in improved material properties that permit increased endothelial cell retention compared to unmodified polyurethane.

As used herein, each of the following terms has the meaning associated with it in this section, absent an express indication to the contrary.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

"Implantation," and grammatical forms thereof, refers to the process of contacting a device with a tissue of an animal in vivo wherein the contact is intended to continue for a period

WO 2005/007034, which, for years without substantial degradation, PCT/US2004/021831 which contact includes, for example, grafting or adhering the device to or within a tissue of the animal and depositing the device within an orifice, cavity, incision, or other natural or artificially-created void in the body of the animal.

5 An "implantable" device is one which is adapted for permanent or temporary insertion into or application against a tissue of an animal such as a human. Examples of implantable devices or components include, but are not limited to, an artificial heart; cardiac pacer leads; automatic implantable cardio defibrillator leads; a prosthetic heart valve; a cardiopulmonary bypass membrane; a ventricular assist device; an annuloplasty ring; a dermal graft; a vascular
10 graft; a vascular, cardiovascular, or structural stent; a catheter; a guide wire; a vascular or cardiovascular shunt; a dura mater graft; a cartilage graft; a cartilage implant; a pericardium graft; a ligament prosthesis; a tendon prosthesis; a urinary bladder prosthesis; a pledget; a suture; a permanently in-dwelling percutaneous device; an artificial joint; an artificial limb; a bionic construct (i.e. one of the aforementioned devices or components comprising a
15 microprocessor or other electronic component); and a surgical patch.

An "oxirane" ring or group is also known as an epoxy ring or group.

A "thiol-reactive functional group" is a moiety capable of reacting with thiol group (-SH) such that a covalent bond is formed between an atom of the compound containing the thiol-reactive functional group and the sulfur atom of the thiol group.

20 A "thiolating agent" is any agent, such as a thiol nucleophile, that introduces a thiol group or a sulfide which is readily transformed to a thiol by, for example, hydrolysis or reduction. Examples of thiolating reagents include, without limitation, thiosulfate, thiourea, trityl- and tert-butylmercaptans, thiocyanate, and thioalkanoic acids such as thioacetic acid. Reagents such as thiosulfate, thiourea, trityl- and tert-butylmercaptans, and thiocyanate require
25 further treatment by, for example, hydrolysis or reduction of the resultant sulfur-containing compound to obtain the desired thiol group. In a preferred embodiment, the thiolating agent is thioacetic acid.

The term "alkyl" refers to a hydrocarbon containing from 1 to 12 carbon atoms unless otherwise defined. An alkyl is an optionally substituted straight, branched or cyclic saturated
30 hydrocarbon group. When substituted, alkyl groups may be substituted at any available point of attachment. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group". Exemplary unsubstituted groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like.
35 Exemplary substituents may include but are not limited to one or more of the following groups: halo (such as F, Cl, Br, I), haloalkyl (such as CCl₃, or CF₃), alkoxy, alkylthio, hydroxy, carboxy

WO 2005/007034 (USPTO/US2004/021831)
(-C(=O)-R), carbonyl (-C(=O)-), epoxy, alkyloxycarbonyl (-C(=O)-OR), alkyloxycarbonyloxy
(-OC(=O)-R), amino (-NH₂), carbamoyl (NH₂C(=O)- or NHRC(=O)-), urea (-NHCONH₂),
alkylurea (-NHCONHR) or thiol (-SH), wherein R in the aforementioned substituents
represents an alkyl radical. Alkyl groups (moieties) as defined herein may also comprise one or
more carbon to carbon double bonds or one or more carbon to carbon triple bonds. Alkyl
groups may also be interrupted with at least one oxygen, nitrogen, or sulfur atom.

The term "biomaterial" as used herein denotes any synthetic biocompatible polymeric
material which is known, or is hereafter developed, as being suitable for in-dwelling uses in the
body of a living being, i.e., which is biologically inert and physiologically acceptable, non-toxic,
and insoluble in the environment of use.


Polyurethanes

In accordance with the teachings of this invention, the polyurethane has at least one
pendant thiol substituent which is either thiol or protected thiol group or a mixture of both.

The term "polyurethane," as used herein, is a polymer that comprises repeating units
having a urethane group in the polymer backbone. Such polymers include, for example,
polyurethane homopolymers, block co-polymers comprising at least one polyurethane block,
and polymer blends comprising such homopolymers and block co-polymers. Illustrative
polyurethanes include but are not limited to F2000 PEU, which is a medical grade polyether-
urethane prepared from 4,4-methylenebis(phenylisocyanate), polytetramethyleneoxide (MW ca.
1,000 g/mol), and 1,4-butanediol as a chain extender (Sulzer Carbomedics, Inc.; Austin, TX);
BIO-SPAN™, which is a medical grade polyurethane-urea and BIONATE™ 80A, which is a
medical grade polycarbonate-urethane (both from Polymer Technology Group Medical, LLC;
Berkeley, CA); and TECOTHANE™ TT-1074A, which is a medical grade polyether-urethane
(Thermedics, Inc.; Woburn, MA). Such polymers include, for example, both polyether
polyurethanes and polyester polyurethanes which may be in the form of homopolymers, block
co-polymers comprising at least one polyurethane block, and polymer blends comprising such
homopolymers and block co-polymers.

A chemical substituent is "pendant" from a backbone of a polymer if it is bound to an
atom of a monomeric unit of the polymer. In this context, the substituent can be pending from a
carbon atom of a backbone, a carbon atom connected to a carbon atom of the backbone by a
chain extender, or a urethane nitrogen of the backbone of the polyurethane.

A "urethane group" is a chemical structure which is part of the backbone of a polymer
and which has the following structure:



The "backbone" of a polymer is the collection of atoms and chemical bonds

A chemical substituent is "pendant" from the backbone of a polymer if it is attached to an atom of a monomeric unit of the polymer, either directly or indirectly, e.g. through a linker moiety.

5 Polyurethanes suitable for the instant invention may be obtained commercially (such as Tecothane; Thermedics Inc., Woburn, MA). Preferably, the polyurethanes are resistant to degradation, suitable for implantation into an animal, and have a chemically accessible nitrogen of the urethane groups.

10 Alternatively, polyurethanes can be made by condensing a diisocyanate (OCN--A--CNO) with a diol (HO--X--OH), with two or more diols having different structures, or with both a diol and a diamine. It is understood that the proportion of end groups corresponding to the diisocyanate and the diol can be controlled by using an excess of the desired end group. For example, if a reaction is performed in the presence of an excess of the diisocyanate, then the resulting polyurethane will have isocyanate (--NCO) groups at each end.

15 Depending on the identity of the reaction products used to form them, polyurethanes can behave as elastomers or as rigid, hard thermosets. If the diisocyanate in the synthesis reaction is, for example, 4,4'-methylenebis(phenylisocyanate), then the resultant polyurethane will be relatively inflexible. If the diol in the synthesis reaction is, for example, polytetramethyleneoxide (i.e., HO--(CH₂CH₂CH₂CH₂O)_k--H, wherein, e.g., k is about 10 to 30),
20 then the resultant polyurethane will be relatively flexible. Methods of selecting polyurethane precursors which will yield a polyurethane having hard and soft segments which confer a desired property (e.g., flexibility, elastomericity, etc.) to the polyurethane are well known in the art.

25 Methods of making segmented polyurethanes are also known in the art. In these methods, one or more types of polyurethane precursors (OCN--P--NCO) are reacted with a chain extending compound (HZ--Y--ZH) to yield a segmented polyurethane. By varying the proportions of different types of polyurethane precursors, their end groups, the identity of the chain extender, and the like, the composition of polyurethane segments in the segmented polymer can be controlled, as is known in the art. Medical grade segmented

30 polyurethanes are usually prepared by condensing a diisocyanate with a polymeric diol having a molecular weight of about 1,000 to 3,000 (e.g., polytetramethyleneoxide for polyether-urethanes or polycarbonatediols for polycarbonate-urethanes) in order to form a polyurethane precursor which is subsequently reacted with an approximately equivalent amount of a chain extender (e.g., a diol such as 1,4-butanediol or a diamine such as a mixture of diaminocyclohexane
35 isomers).

The lipid molecules which may be used in the practice of this invention are preferably

Two 2005/007034 to cover membranes such as, without limitation, PCT/US2004/021831-g., phosphatidylcholine, sphingomyelin, phosphatidylserine, and phosphatidylethanolamine), steroid lipids (i.e. lipids containing a steroid ring structure and a nonpolar hydrocarbon tail), glycolipids, and derivatives thereof. Steroid lipids (e.g. cholesterol and derivatives thereof) are preferred for immobilization on the polyurethane as the steroid ring is nonbiodegradable. The lipids attached to the polyurethane may all be the same or more than one type of lipid may be attached, if desired. Additionally, membrane proteins may be added exogenously and allowed to interact with the lipids immobilized on the polyurethane to organize pseudomembranes.

The lipid molecule may be derivatized for attachment of a thiol group. This may be conveniently carried out by reacting the lipid molecule with an oxirane-containing compound, preferably an epihalohydrin. Suitable epihalohydrins which can be employed for this purpose include, for example, epichlorohydrin, epibromohydrin, epiodohydrin, methylepichlorohydrin, methylepibromohydrin, methylepiiodohydrin, ethylepichlorohydrin, ethylepibromohydrin, ethylepiiodohydrin, propylepichlorohydrin, propylepibromohydrin, propylepiiodohydrin, butylepichlorohydrin, butylepibromohydrin, butylepiiodohydrin, and the like.

The thiol group may be thereafter introduced by reaction between the oxirane-containing lipid derivative and the thiolating agent. Other methods (e.g., the replacement of the hydroxy group with a thiol function via cholesteryl tosylate and thiuronium salt) can also be used to provide the lipid with a highly reactive thiol group. Alternatively, modified cholesterol containing a reactive thiol group, such as thiocholesterol, are also commercially available (Sigma, St. Louis, MO).

The linker moiety used to attach a lipid to a polyurethane in practicing the present invention is preferably the residue of a compound which comprises an alkyl moiety that joins at least one reactive group that is a thiol-reactive functional group and at least one reactive group capable of attachment to the urethane group nitrogen of the polyurethane. Preferably, the linker moiety is nondegradable. The linker moiety may be derived from a dihaloalkane having from 1 to about 12 carbon atoms with the halogens substituted on the terminal carbon atoms, such as 1,4-dibromobutane; 1,3-dibromopropane; 1,5-dibromopentane; and 1,6-dibromohexane. The compound providing the linker moiety may also comprise a halogen and an epoxy group thereby providing the polymer with pendant glycidyl groups which may be readily reacted with thiolated lipids (see, for example, the reaction of polyurethanes with epibromohydrin in Alferiev, I.S., J. Polym. Sci., Part A: Polym. Chem., 2002, 40:4378-4385). The linker moiety may also be interrupted with at least one sulfur, nitrogen, or sulfur atom and further comprise substituents such as, but not limited to, hydroxy groups and carbonyl groups. Reaction between polyurethane and the multifunctional linker reagent is also described in details in copending U.S. patent application entitled U.S. Patent Application No. 10/672,893 filed on September 26,

MAKING THE SAME and U.S. Patent Application No. 10/672,892, filed on September 26, 2003, entitled DERIVATIZED POLYURETHANE COMPOSITIONS WHICH EXHIBIT ENHANCED STABILITY IN BIOLOGICAL SYSTEMS AND METHODS OF MAKING THE SAME (this application is a continuation-in-part of Application No. 09/985,316, filed on November 2, 2001, which is a continuation of Application No. 09/620,857, filed on July 21, 2000, now U.S. Patent No. 6,320,011, issued on November 20, 2001 which are incorporated herein in their entireties.

Other methods of covalently binding a lipid to a polyurethane by use of a linker moiety that is different than the dihaloalkanes described above would be readily apparent to a skilled artisan. For example, polyurethane may be modified with pendant carboxy groups via N-hydroxysuccinimide esterification and subsequently reacted with an aminated lipid. More specifically, polyurethanes can be provided with pendant carboxy groups (as described in U.S. Patent No. 6,320,011) either by direct carboxyalkylation (see, e.g., Example 2 of U.S. Patent No. 6,320,011) or by carboxyl derivatization of pendant omega-bromoalkyl groups (see, e.g., Example 10 of U.S. Patent No. 6,320,011). The carboxy groups can then be activated via N-hydroxysuccinimide esterification (U.S. Patent No. 6,320,011) and reacted with an aminated lipid such as cholesterylamine (Kan, C.C., et al., Biochemistry 1992, 31(6), 1866-74). The reaction scheme is exemplified in Figure 7.

The chemical reactions utilized to make the polymer material of the invention are easily performed. In the preferred approach, a lipid molecule is reacted with an oxirane-containing compound in such a manner that the oxirane-containing compound is covalently bound to the lipid. The epoxy ring substituent of the lipid is subsequently opened by a reaction with an epoxy-reactive thiolating agent, thereby yielding a thiol-substituted lipid, in which the thiol group is optionally protected. The ring opening results in formation of a covalent bond between the epoxy-reactive thiolating agent and an atom of the epoxy ring. If present, the protective group on the thiol group is then removed.

Additionally, a polyurethane biomaterial is modified to contain a thiol-reactive functional group. Such a functional group may be added directly to the nitrogen atom of the urethane group or, preferably, through a linker moiety. Subsequently, the thiol-substituted lipid molecule is reacted with the polyurethane containing a thiol-reactive functional group, thereby yielding the desired lipid-modified polyurethane.

Implantation devices comprising the lipid modified polyurethanes of the invention are advantageously seeded with cells prior to implantation of the device. Typically, the cells are autologous endothelial cells.

There are multiple techniques known in the art for the seeding of selected cells to an

Typically, the implantation device is incubated in vitro, optionally with rotation, to allow the binding of the endothelial cells to the surface of the device. After several hours or days of culture, the device may be implanted into the host. Alternatively, the endothelial cells may be mixed with blood prior to application onto the implantation device.

More specifically, the number of cells deposited on the device may be between about 10^3 cells/cm² and 10^{12} cells/cm² of device surface, typically about 5×10^5 cells/cm². The cells are deposited in any convenient sterile medium, e.g. phosphate buffered saline (PBS), normal saline, M199, Dulbecco's Modified Eagles Medium (DMEM), and the like. The volume of medium will be sufficient to resuspend the cells, generally ranging from about 1 to 25 ml of medium.

After deposition, the prosthesis may be implanted immediately into the recipient or more preferably be maintained in culture for a period of time. The culture conditions are conventional for endothelial cells, for example, the prosthesis may be deposited in a plate or well containing medium and fetal calf serum, then incubated at 37 C. The culturing medium may be changed at least every 2-3 days, usually daily. The prosthesis will generally be maintained in culture for not more than about three weeks, usually for not more than about two weeks, and preferably will be used within about one week.

Cells employed for seeding on the implantable device may be obtained by any method known in the art. Cells may be obtained at the time of the implantation procedure using standard biopsy techniques, whether the procedure is angioplasty, open field surgery or for diagnostic purposes. The cells may also be dissociated with collagenase or trypsin and seeded directly into a matrix as exemplified below for immediate implantation or for culturing in vitro as required to generate the number of cells to be implanted. Specifically, cells may be isolated by standard methods described in, for example, Gimbrone, M. (1976) Progress Hemostasis and Thrombosis 3:1-28 and US Patent No. 5,131,907.

2.1 Materials

Lithium-tert-butoxide, Histopaque-1077, sodium hydroxide, cholesterol, tetrahydro-fluorane (THF) were purchased from Sigma (St. Louis, MO). Tecothane[®] TT1074A, an aromatic polyether polyurethane, was obtained from Thermedics Inc. (Woburn, MA), purified and characterized by ¹H NMR as reported previously³. N,N-dimethylacetamide (DMAC) was purchased from Aldrich Chemicals. 4',6-Diamidino-2-phenylindole (DAPI) fluorescent stain was purchased from Vector Labs (Burlingame, CA). Glass microscope slides were obtained from Fisher Scientific (Pittsburgh, PA). EGM-2 culture media was purchased from Clonetics (San Diego, CA). Dulbecco's modification of Eagle's medium (DMEM) was purchased from Cellgro (Herndon, VA) and Trypsin/EDTA was acquired from Gibco (Grand Island, NY).

Bovine aortas, obtained from a local abattoir, were cleaned of excess tissue and cut longitudinally. A warmed solution of DMEM (supplemented with 10% Fetal Bovine Serum, non-essential amino acids and penicillin streptomycin) containing collagenase (2.5 mg/ml, Gibco) was pipetted onto, up, and back onto to the inside of the aorta for 2-5 minutes. The released cells in suspension were collected, centrifuged, and resuspended in culture media. The cell suspension was put through a 300 mesh sieve and the top layer containing cell clusters was collected and plated on tissue culture plates. BAEC's were maintained (37°C, 5% CO₂) in DMEM supplemented with 10% FBS and penicillin streptomycin. BAEC's used in this study were between passages 5-12.

Sheep blood outgrowth endothelial cells (BOEC's) were prepared from freshly drawn peripheral blood using a previously published method ⁷ and all procedures and animal husbandry were in compliance with NIH standards pertaining to the care and use of laboratory animals as approved by the IACUC of the the University of Minnesota. Briefly, heparinized peripheral blood (100 mls) was collected from a juvenile sheep by venipuncture. Mononuclear cells were isolated from blood using Histopaque-1077, according to the manufacturer's instructions. The buffy coat was collected, washed with HBSS and resuspended in EGM-2 culture media. The resuspended cells were seeded onto a tissue culture dish precoated with acetic acid denatured collagen. The culture media was changed every other day and the cells were subcultured using Trypsin/EDTA. Endothelial cell phenotype was confirmed using uptake of acetylated LDL, immunocytochemistry for P1H12 and VE-cadherin ⁷⁻⁹.

2.3 Preparation of cholesterol modified Tecothane®

A schematic diagram of the reactions used for covalent binding of cholesterol to the urethane hard segments by the reaction of bromobutylated Tecothane® with 2-hydroxy-3- β -cholesteryloxypropanethiol is presented in Figures 1 and 2. Glycidyl cholesterol (Figure 1) was synthesized by dissolving cholesterol in DMAc under a flow of dry argon and adding 1 M lithium tert-butoxide in hexanes. After cooling to 5°C, freshly distilled epibromohydrin was added and the mixture was stirred at 3-5°C for 2 hours and allowed to slowly come to room temperature (21-23°C) where it was incubated for an additional hour. The reaction mixture was diluted with 0.5% aqueous KHCO₃ and extracted with three administrations of n-heptane. The combined organic layers were dried over Na₂SO₄. After filtration from the desiccant, the solvent was removed *in vacuo* and the residue was purified by flash-chromatography on silica gel employing elution with hexane, hexane/toluene (1:1 mixture), and toluene. The fractions containing pure glycidyl cholesterol were pooled and dried *in vacuo* until crystallization

Freshly distilled thioacetic acid was dissolved in DMAc under argon protection and cooled to -10°C . A 0.35 M freshly prepared solution of $(\text{Bu}_4\text{N})_2\text{B}_4\text{O}_7$ in DMAc was added. Glycidyl cholesterol, from above, was dissolved in DMAc and added to the resulting solution. The mixture was allowed to react for 2 hours at 0°C and then poured into ice-cold water. The product was extracted with decreasing volumes of n-heptane. The organic layers were dried at 4°C over Na_2SO_4 , filtered and dried *in vacuo*. Crude 1-acetylthio-3- β -cholesteryloxy-2-propanol was dissolved in THF and mixed with a 2.7 M solution of NH_2OH in 2-propanol (100 mmol) under argon. The mixture was allowed to react at room temperature for 5 hours and diluted with 1.2% aqueous H_3PO_4 . Organic solvents were removed *in vacuo* below 30°C together with a part of water. The resultant solid precipitate was filtered off, thoroughly washed with water and dried *in vacuo*. Crude 2-hydroxy-3- β -cholesteryloxypropanethiol was purified by flash-chromatography (silica gel, hexane then hexane-ethyl acetate, 10:1), and analyzed for purity via ^1H NMR.

Cholesterol modified Tecothane[®] (Figure 2) was bromobutylated as described previously¹, and characterized by ^1H NMR (Figure 9). The results revealed that ca 20% of urethane segments were modified with pendant 4-bromobutyl groups (Figure 9). The polymer was dissolved in DMAc under argon and cooled to -2°C . A solution of 2-hydroxy-3- β -cholesteryloxypropanethiol from above, in DMAc and a freshly prepared 0.24 M DMAc-solution of $(\text{Bu}_4\text{N})_2\text{B}_4\text{O}_7$, were added. The mixture was stirred at -1 to 1°C for one hour and acidified with acetic acid (10.5 mmol). The reaction solution was then filtered and the polymer was precipitated with cold (-12°C) methanol. The precipitate was washed with methanol, alternating with 2-propanol and stirred constantly with large amounts of 2-propanol, methanol, and water and dried under 0.05 mm Hg conditions. ^1H NMR (see Fig. 9) analysis of this polymer indicated covalent attachment of cholesterol to about 20% of the urethane segments via noncleavable, sulfide bonds corresponding to approximately 0.4 mmol of pendant cholesterol moieties per gram of polymer.

Cholesterol modified Tecothane[®] was highly soluble in tetrahydrofuran (THF), comparable to unmodified Tecothane[®]. For solvent casting films, Tecothane[®]-cholesterol (5.6 gm/100ml in THF) and unmodified Tecothane[®] (5.2gm/100ml in THF) thin films were solvent cast onto Teflon-foil coated petri dishes, and were air dried in a fume hood. Film thickness ranged from 159 to 220 microns. These thin films were used in all of the material and cell culture studies described, and where relevant differences were noted between the air-dried side and the surface prepared in contact with Teflon. Methodology for preparing polyurethane films

Material properties of the modified and unmodified polyurethane films were assessed using a Perkin Elmer (Wellesley, MA) DMA 7. Samples were cooled to -68°C and heated to 120° C at a rate of 3° C min⁻¹. Data measuring material elasticity (Storage Modulus) and mechanical loss factor (Tan Delta), which reflects differences in calorimetry parameters between materials, at a test frequency of 10 Hz were analyzed using the Pyris software package (Perkin Elmer).

The water contact angle on unmodified or cholesterol modified Tecothane was measured on a custom built imaging-goniometer system using established methodology ¹⁰, and was recorded as the average of 8 measurements of each sample. The sessile drops were immediately visualized using a CCD camera (Edmund Scientific Co., Barrington, NJ) and contact angle measurements were analyzed using Scion Image analysis software package (Scion Inc., Frederick, MD).

Films composed of Tecothane or cholesterol-modified Tecothane were cut into 1 cm square sections (thickness ≈ 150 μm) and placed in the bottom of a 24 well plate. BAEC's were trypsinized and added to each well (10,000 cells/well). Cells were incubated at 37°C. At fifteen-minute intervals, the polyurethane films were gently washed with PBS and adherent cells were fixed with cold 4% paraformaldehyde. Cells were quantified by staining with DAPI, a fluorescent, nuclei specific stain, and counted under 200X magnification with the appropriate fluorescent filter set using a Nikon TE-300 (Nikon Inc., Tokyo, Japan) inverted microscope.

Glass microscope slides (73 x 38 x 1 mm) were treated for 1 hour with 2 M NaOH ¹¹, washed with distilled water, autoclaved, and inserted into Teflon coated casts with identical dimensions. Tecothane or cholesterol modified Tecothane was dissolved in THF at a final concentration of 20 mg/ml and 3 mls was added to each slide. The coated slides were loosely covered with foil and the THF solvent was evaporated overnight at room temperature. The uniform thickness of the polyurethane coating was 10 μm. Trypsinized BAEC's or BOEC's were suspended in DMEM or EGM media respectively, supplemented with 10% fetal calf serum and penicillin-streptomycin (100 μg/ml), and were seeded directly on the polyurethane-coated slides. Cells were grown until confluence and then the glass slides were inserted into a parallel plate shear chamber forming a flow channel (264 μm height X 15.4 mm width 58 mm length)

WO 2005/007034 ~~between the monolayer and the fabricated polycarbonate plate~~ ¹¹. Non-patented, ~~air~~ CT/US2004/021831 ~~air~~
flow utilized serum supplemented medium at 37°C, and was controlled by maintaining the flow
rate of a peristaltic pump at 43 ml/min for glass slides and 40 ml/min for polyurethane coated
slides. Shear stress (T_w) was calculated by the following equation

$$T_w = \frac{6\mu Q}{w(x)^2}$$

where μ is the media viscosity, w is the width of the flow chamber, x is the height of the flow
chamber, and Q is the flow rate. A shear stress of 25 dynes/cm² was applied, approximating
systemic arterial shear conditions. After exposure to shear for set times of 30, 60 and 120
minutes, the slides were detached from the chamber, washed in PBS for 10 minutes, and then
fixed in 4% paraformaldehyde. Cells were stained with DAPI and quantified as the number of
DAPI positive cells in a minimum of 9 random, 200 X fields/slide.

Cholesterol-modified and unmodified polyurethane films were imaged using a Model
3100 multi-mode atomic force microscope (Digital Instruments, Santa Barbara, CA). Imaging
was performed in the intermittent non contact (tapping) mode, using oscillating linear Si tips at
resonance frequency of 315.81KHz. Each data scan was collected over a 10 μ m² area at a
scanning frequency of 0.50 Hz. The 2D and 3D morphology, as well as surface roughness data
were collected and analyzed using the Nanoscope version 4.43r6 software package (Digital
Instruments, Santa Barbara, CA).

2.10. Fourier Transform Infrared Spectroscopy-Attenuated Total Reflectance

Fourier transform infrared spectra of the samples were measured by attenuated total reflectance
spectroscopy (FTIR-ATR) using a Nicolet 5-Protège 460 spectrophotometer-E.S.P. (Nicolet,
Madison, WI). All spectra were the result of 200 scans collected at a resolution of 2 cm⁻¹ at a
45° angle of incidence. All spectra were recorded under identical conditions and adjusted for
atmospheric water vapor and carbon dioxide transmittance by subtraction of the appropriate
reference spectrum using the Omnic software package (Nicolet). Polyurethane film thickness
was approximately 150 μ m.

Data were calculated as means \pm standard error (SE). Student's t -test was used to determine the
significance of differences. Statistical significance was noted with $p \leq 0.05$.

FTIR analysis (Figure 2) was used to compare the surface chemistry of the cholesterol
modified and unmodified polyurethane on both the air exposed and non-air exposed sides of the

WO 2005/007034 PCT/US2004/021831
polyurethane. The FTIR spectra for the air exposed surfaces (Figure 2 A&B) were identical to the non-air exposed sides of their respective films (data not shown). The peak assignment as shown in Table 1 revealed peak shifts in the cholesterol modified Tecothane® at 3302, 1680, 743 and 717 cm⁻¹. The peak shift at 3329 in the unmodified polyurethane and the appearance of the displaced peak at 3302 most likely represent a shift in the hydrogen bonding between the nitrogen and the hydrogen in the hard segment. This bond was the target of the bromobutylation step and would thus be altered in the cholesterol containing polyurethane^{1,3,12}. Likewise the appearance of peaks at 1680, 743 and 717 in the cholesterol-modified polyurethane probably represents the carboxyl bond in cholesterol (1680) and the sulfur (743 and 717) of the pendant molecules. Thus, these data show the presence of cholesterol moieties at or near the polyurethane surface.

To determine the changes in material properties resulting from appending cholesterol moieties to the urethane hard segment of Tecothane®, DMA was used to compare changes in the glass transition temperature (T_g), the melting temperature (T_m), and mechanical behavior (storage modulus). Overall cholesterol modification resulted in no net DMA changes in the ambient to physiologic temperature range. However, as shown in Figure 3A, appending cholesterol moieties to the urethane hard segment increased the storage modulus at lower temperatures. Figure 3B shows unmodified Tecothane® had a T_g of ~51°C which is in accordance with previously published results¹². In contrast, cholesterol modified polyurethane had a higher T_g of -24°C. The melting temperature was approximately 112°C for unmodified Tecothane and 73°C for cholesterol modified Tecothane.

Cholesterol modified polyurethane's surface properties were compared to unmodified polyurethane in contact angle studies and AFM investigations. The contact angle of cholesterol modified polyurethane was about 30° greater than the unmodified surface (Table 2). These differences are statistically significant ($p = 0.02$) and thus demonstrate increased hydrophobicity due to covalently attached cholesterol. Atomic force microscopy studies compared the air exposed surface topography of cholesterol modified and unmodified polyurethane (Figure 4). The unmodified polyurethane showed widespread ridges and valleys at the air exposed surfaces. Cholesterol modified polyurethane demonstrated qualitatively smoother surfaces with fewer surface irregularities than unmodified polyurethane. Both types of polyurethane films showed increased smoothness per AFM on the non-air exposed surfaces (data not shown).

3.2 Cell-polyurethane interactions

The kinetics of attachment of endothelial cells (BAEC's) to the cholesterol-modified polyurethane surface was compared to unmodified polyurethane and tissue culture polystyrene surfaces. BAEC's were seeded using 10% FBS supplemented medium onto the three types of

surfaces and sampled every fifteen minutes quantitating attached cells. A separate study substituting serum free media for normal growth media assessed the contribution of exogenous lipids and other serum components from the supplemented media. *Figure 5A* shows the average number of BAEC's per field over the 45-minute interval of the experiment. After thirty minutes, cell attachment to cholesterol modified polyurethane was not significantly different than cell attachment to either plastic or unmodified polyurethane. However, by the 45-minute cessation of the study, cell attachment on the cholesterol modified polyurethane in the presence of 10% FBS was significantly greater than observed with the unmodified polyurethane ($p=0.006$) (*Figure 5A*). In fact more BAECs attached to the cholesterol modified polyurethane than to the tissue culture treated plastic; however, these differences were not found to be significant ($p=0.070$). Comparisons of cell attachment to cholesterol modified polyurethane in the presence and absence of serum (*Figure 5B*) showed similar trends to the serum free studies and suggests that exogenous lipids and other serum components do not influence the initial attachment of BAEC's to cholesterol-modified polyurethane.

We compared retention of an intact endothelium, growing on either a cholesterol modified or unmodified polyurethane substrate under fluid induced mechanical forces, by quantifying the number of both BAEC's and separately BOEC's remaining on the respective substrates after a fixed time exposure to simulated arterial shear stress (25 dynes/cm²). In the BAEC studies, phase microscopy (6 A-L) was performed to qualitatively evaluate shear stress induced changes in the endothelial cell morphology after 0.5, 1 and 2 hours. At the initiation of the study, cells growing on glass and cholesterol modified polyurethane (6A and E) showed a characteristic "cobblestone morphology". Cells growing on unmodified polyurethane (6I) had a comparable morphology. After one hour (6 G) of exposure to fluid flow at 25 dynes/cm², cells growing on cholesterol modified polyurethane retained their morphology, and continued to do so at two hours as well (6H). The cells cultivated on the unmodified polyurethane substrate failed to maintain inter-cellular organization and extensive cell loss was apparent after 1 hour (6K). Endothelial cells continued to be shed from unmodified polyurethane up to the 2 hours conclusion of the study (6L). Cells seeded onto NaOH treated glass slides (*Figure 6A-D*) were largely retained after 1-hour exposure to shear. However, after two hours of shear exposure, BAEC's growing on NaOH treated glass slides also demonstrated regions of detachment from the surface (*Figure 6D*).

A quantitative assessment of BAEC's exposed to shear on the three test surfaces was performed. *Figure 6M* shows the average percent of BAEC's retained after exposure to 25 dynes/cm² of laminar flow for 0.5, 1 and 2 hours. After 30 minutes exposure to flow, cell retention was virtually identical on the cholesterol modified polyurethane, unmodified polyurethane and the tissue culture treated glass control. However, after 60 minutes exposure to

two 2005/007034 at Significantly greater ($p = 0.0003$) endothelial cell retention on cholesterol-modified polyurethane compared to unmodified polyurethane substrates (Figure 6M). Only $60.3\% \pm 4.5$ ($n=9$) of the original BAEC's were retained on unmodified polyurethane when exposed to 25 dynes/cm² shear stress for only one hour. After 120 minutes exposure to 25 dynes/cm² shear flow, cell retention was two-fold higher on cholesterol modified polyurethane compared to unmodified polyurethane. These results were statistically significant ($p = 0.0070$). In addition, cholesterol-modified polyurethane was not statistically different than NaOH treated glass in retaining endothelial cells at 2 hours.

Blood outgrowth endothelial cells (BOEC's) are a recently characterized endothelial cell derived from a putative endothelial precursor cell in peripheral blood ^{7,9}. Since the use of BOEC's in vascular implant coatings is a relatively new focus, little data exists regarding the behavior of these cells under shear conditions, and no data exists on these cells seeded directly onto to polyurethane films ¹³. We therefore exposed BOEC's grown to confluence on polyurethane, glass, or cholesterol modified polyurethane to 25 dynes/cm² for 0.5, 1, and 2 hours. Phase microscopy (Figure 14 A-L) was used to evaluate changes in BOEC morphology after two hours exposure to shear at 25 dynes/cm². BOEC's seeded onto polyurethane modified cholesterol and NaOH treated glass retained their cobblestone morphology and very little cell loss was noted after two hours (Figure 7D&7H). In contrast, after 0.5 or 1 hour exposure to 25 dynes/cm², significantly fewer BOEC's cultured on unmodified polyurethane (Figure 7K) were retained compared to BOEC's cultivated on either glass or cholesterol modified polyurethane. The loss of BOEC's from the unmodified polyurethane surfaces continued throughout the experiment, and at two hours, only isolated islands of about 20 cells with evidence of cell rounding were seen throughout the film (Figure 7L). A quantitative assessment of cell retention (Figure 7M) showed that cholesterol modified polyurethane and tissue culture treated glass retained about 20 fold more BOEC's than the unmodified polyurethane substrate. There were no significant differences between the BOEC results (re. cell retention) on glass or cholesterol modified Tecothane ($p = 0.124$).

This work is the first demonstration of covalent attachment of cholesterol to a polyurethane using the bromo-alkylation methodology developed by our laboratory. Mature arterial endothelial cells seeded on cholesterol modified polyurethane demonstrated significant greater retention under simulated arterial shear stress conditions compared to nonmodified polyurethane. These data are also the first demonstration of blood outgrowth endothelial cell adhesion directly to a modified polyurethane surface. Our BOEC data show multifold greater adhesion under arterial level shear forces on cholesterol modified polyurethane surfaces compared to unmodified polyurethane. These results imply that cholesterol modified

WO 2005/007034 is hypothetically well suited for fabrication of BOEC PCT/US2004/021831 lar implants.

Other strategies for seeding surface-modified polyurethane with endothelial cells in order to decrease thrombogenicity have been reported. Polymerized methacrylic acid was grafted to porous polyurethane scaffolds and was shown to enhance HUVEC proliferation¹⁴. Zhu reported a process in which biocompatible macromolecules (collagen, chitosan, or collagen) were immobilized on an aminolyzed polyurethane surface¹⁵. Although both studies showed favorable proliferation results, cell retention under shear stress was not investigated.

The use of covalently attached RGD domains on polymeric biomaterials has been relatively successful in enhancing endothelial cell affinity in vascular grafts. Seifalian and colleagues characterized endothelialisation of polyurethane vascular grafts modified with a three dimensional honeycombed structure¹⁶ as well as surface bound collagen¹⁷ or RGD¹⁸ or RGD/Heparin¹⁹. HUVEC retention with the RGD/Heparin surface under pulsatile shear flow (25 dynes/cm²) was 75% when seeded upon RGD/Heparin coated polyurethane¹⁹. Chen and colleagues studied polyurethane crosslinked with either a commercially available epoxide or the same polyurethane coated with a cellulose binding domain RGD fusion protein contained within a gelatin matrix; human umbilical vein endothelial cells (HUVEC's) retention on these surfaces was 43% and 63% respectively, after three hour exposure to simulated arterial flow²⁰.

Endothelial seeded vascular grafts, composed of polytetrafluoroethylene, are currently being used in clinical trials^{21,22}. However, harvesting autologous blood vessel derived endothelial cells from patients is an important limitation. BOEC's represent an accessible endothelial cell source and both *in vitro* and *in vivo* data has demonstrated their usefulness in seeding vascular grafts^{13,23-25}. Sheep studies demonstrated successful seeding of a decellularized vascular arterial heterograft using BOEC's²⁴. In addition these same studies demonstrated that BOEC seeded grafts remained patent and demonstrated nitric oxide production that mediated vascular relaxation and contractile activity. Interestingly, it was noted that the seeded BOEC's had poor retention when preconditioning shear stress was raised stepwise from 1 to 25 dynes/cm²²⁴, when the preconditioning conditions were gradually increased very few cells were displaced²⁴. Our data presented in Figure 7 show almost complete cell retention when BOEC's were transferred from static cell culture conditions to immediate high shear stress for two hours. Thus, these prior studies clearly demonstrate the feasibility of BOEC's as a source of autologous endothelial cells for seeding vascular grafts. Similarly our data demonstrate that BOEC's can be used to directly seed our novel cholesterol modified polyurethane and remain seeded under simulated arterial shear stress conditions.

Our material characterization studies of the cholesterol modified polyurethane showed a smoothed surface topography and increased surface free energy, strongly suggesting that the

modification created a lipid enriched surface. Previous work by others described the synthesis and biocompatibility of a new polyurethane formulated by combining cholesterol containing diols with diisocyanates ²⁶. This novel polyurethane configuration had diminished platelet attachment and reduced protein absorption ^{26,27}. However, no studies regarding endothelial cell compatibility were reported with this cholesterol modified polyurethane.

The ideal material properties for optimal endothelial seeding have yet to be determined. Our results strongly suggest that endothelial cell attachment is at least in part a function of hydrophobic interactions between cells membrane and the surface. A similar mechanism was proposed by Sakurai and colleagues who describe cell attachment as a two step process ⁶. The first step is defined as a passive attachment which involves participation of hydrophobic and van der Waals interactions ⁶. The enhanced rapid affinity between BAEC's and cholesterol modified polyurethane, shown in Figure 5, supports the view that such a passive mechanism may occur with attachment to cholesterol modified polyurethane. Their second hypothesized step ^{6,28} of cell attachment requires cellular interactions with the biomaterial, as reflected by the cell retention on cholesterol-modified polyurethane observed under arterial shear in the present study.

Thus, cholesterol can be covalently attached to polyurethane via bromoalkylation chemistry involving the urethane nitrogens. This modification confers profound differences in chemical, mechanical and material properties compared to unmodified polyurethane, resulting in a qualitatively smoother surface with a higher surface energy. Cholesterol modified polyurethane demonstrates significantly increased endothelial cell adhesion post-seeding under arterial shear for both mature endothelial cells and endothelial precursors.

The following examples provide further details regarding the practice of the invention. These examples are provided for illustrative purposes only, and are not intended to limit the invention in any way.

EXAMPLE I:

Attachment of a thiol group to cholesterol

This example describes the specific conditions employed in carrying out the reaction scheme shown in Figure 1.

Cholesterol (5.80 g; 15 mmol; Sigma, St. Louis, MO) was dissolved in 76 ml dry N,N-dimethylacetamide (DMAc) under a flow of dry argon. The solution was cooled to 10 °C and 15 ml (15 mmol) of a 1.0M solution of lithium tert-butoxide in hexanes (Sigma) was added. After further cooling to 5 °C, 10 ml (117 mmol) of freshly distilled epibromohydrin was added

21-23 °C and the reaction was allowed to continue for another hour. The reaction mixture was then diluted with 500 ml of 0.5% aqueous KHCO_3 and extracted with 350 ml n-heptane and then twice more with 100 ml n-heptane. The combined organic layers were dried over Na_2SO_4 . After filtration from the desiccant, the solvent was removed in vacuo. The syrupy residue (7.3 g) was purified by flash-chromatography on silica gel employing elution with hexane, hexane/toluene (1:1 mixture), and toluene. The fractions containing pure glycidyl-cholesterol (thin layer chromatography (TLC)-monitoring) were pooled and dried in vacuo until crystallization occurred. The procedure yielded 4.25 g glycidyl-cholesterol (64%). The product displayed an R_f of 0.38 by TLC (silica gel, n-heptane/ethyl acetate, 85:15 by volume). The signals (only those produced by the glycidyl group not present in the starting cholesterol) obtained by ^1H NMR analysis of the product are as follows: 2.62 and 2.87 (both m, 1H and 1H, two non-equivalent H of oxirane CH_2), 3.15 (m, 1H, CH), and 3.47 and 3.72 (both m, 1H and 1H, diastereotopic H of CH_2O).

Freshly distilled (at 115 mm Hg) thioacetic acid (4.3 ml, 60 mmol) was dissolved in DMAc (60 ml) under argon protection and cooled to -10 °C. A 0.35 M freshly prepared solution of $(\text{Bu}_4\text{N})_2\text{B}_4\text{O}_7$ in DMAc (42 ml, 15 mmol) was added and the temperature (which rose to -1 °C) was returned to -10 °C. Glycidyl -cholesterol (4.24 g, 9.57 mmol) dissolved in DMAc (25 ml) was added and the mixture was allowed to react for 2 hours at 0 °C and then poured into ice-cold water (700 ml). The excess of thioacetic acid was distilled off in vacuo at less than 40 °C with a part of water. Approximately 100 ml of distillate was collected. The residue was extracted with 350 ml n-heptane and then 150 ml n-heptane. The organic layers were dried at 4 °C over Na_2SO_4 , filtered and dried in vacuo. Crude 3-acetylthio-2-hydroxypropyl-cholesterol (5.9 g) was dissolved in tetrahydrofuran (THF; 30 ml) and mixed with a 2.7 M solution of NH_2OH in 2-propanol (37 ml; 100 mmol) under argon. The mixture was allowed to react at room temperature for 5 hours and diluted with 1.2% aqueous H_3PO_4 (300 ml). Organic solvents were removed in vacuo at less than 30 °C. The resultant solid precipitate was filtered off, thoroughly washed with water and dried in vacuo. Crude 3-mercapto-2-hydroxypropyl-cholesterol (4.30 g) was purified by flash-chromatography (silica gel, hexane then hexane/ethyl acetate, 10:1). The yield of pure crystalline 3-mercapto-2-hydroxypropyl-cholesterol was 3.33 g (73%). The product displayed an R_f of 0.26 by TLC (silica gel, n-heptane/ethyl acetate, 85:15 by volume). The signals (only those not present in the starting cholesterol) obtained by ^1H NMR analysis of the product are as follows: 2.59 -2.73 (m, 2H, CH_2S), 3.49 and 3.56 (both m, 1H and 1H, diastereotopic H of CH_2O), and 3.79 (m, 1H, CH).

EXAMPLE II:

This example describes the specific conditions employed in carrying out the reaction scheme shown in Figure 2.

5 Tecothane TT-1074A (15.8 g; containing approximately 38 mmol of urethane NH groups; Thermedics Inc., Woburn, MA) was soaked in toluene (150 ml) for 60 hours. After removal of the excess solvent, the swollen polymer was dried in vacuo at 40 C and dissolved in DMAc (300 ml) under a flow of dry argon. Freshly distilled (at 15 mm Hg) 1,4-dibromobutane (15 ml, 126 mmol) was added and the solution was cooled to -6 C. A 1.0 M solution of lithium tert-butoxide in hexanes (7.6 ml; 7.6 mmol; Sigma) diluted with dry DMAc (20 ml) was
10 added over a ten minute period with vigorous stirring at -5 to -6 C. The resultant mixture was stirred at -1 to 1 C for one hour with continued argon protection and then acidified with acetic acid (6.5 ml). The reaction mixture was poured into a large volume of cold (-55 C) methanol (1200 ml). The resulting coagulate of polymer was separated and thoroughly washed with methanol followed by 2-propanol and subsequently dried in vacuo (0.5 mm Hg) at room
15 temperature. The crude polymer was redissolved in dimethylformamide (DMF; 275 ml). The solution was then filtered and the polymer was precipitated with cold methanol. The precipitate was washed with large volumes of methanol and water and subsequently stirred for 16 hours with a large amount of water at 4 C. The solution was dried in vacuo (0.04 mm Hg) at room temperature to yield 15.64 g of the bromobutylated Tecothane represented in Figure 2. ¹H NMR
20 spectral analysis of bromobutylated Tecothane (see Alferiev, I. et al. 2001. J. Polym. Sci. Part A: Polym. Chem. 39:105-116) indicated that the modification of urethane sites with 4-bromobutyl groups was 20% corresponding to approximately 0.45 mmol of 4-bromobutyl groups per gram of polymer.

The bromobutylated Tecothane (1.14 g, containing approximately 0.5 mmol of 4-bromobutyl groups) described above was dissolved in DMAc (20 ml) under argon and cooled to
25 -2 C. A solution of 3-mercapto-2-hydroxypropyl-cholesterol (0.495 g, 1.04 mmol) in DMAc (8 ml) was added and a freshly prepared 0.12 M DMAc-solution of (Bu₄N)₂B₄O₇ (5 ml, 6 mmol) was also added. The mixture was stirred at -1 to 1 C for one hour and acidified with acetic acid (0.12 ml, 2 mmol). The reaction solution was then filtered and the polymer was precipitated
30 with methanol (150 ml). The precipitate was washed with methanol alternating with 2-propanol and stirred consequently with large amounts of 2-propanol, methanol, and water and dried under 0.05 mm Hg conditions. The procedure yielded 1.31 g of cholesterol-modified Tecothane. ¹H NMR analysis of this polymer (DMF-d₇) indicated covalent attachment of cholesterol to 20% of the urethane segments via noncleavable sulfide bonds (see Fig. 2) corresponding to
35 approximately 0.4 mmol of pendant cholesterol moieties per gram of polymer.

Cell Adhesion to Cholesterol Modified Polyurethane

Successful cell engraftment to a biological or an artificial surface is an orchestrated, multiple step process involving cell attachment to the surface and the ability of the cells to receive appropriate physical and chemical signaling cues from the microenvironment to maintain cell viability. The cellular affinity and cell viability of cholesterol modified polyurethane was compared to unmodified polyurethane and plastic in in vitro culture environments. To determine the cellular attachment properties of the three surfaces, equal concentrations (7.5×10^4 cells/ml) of rat cardiac smooth muscle cells (A10; American Type Culture Collection; Manassas, VA) were dispensed into individual wells of a 24 well flat bottomed plate (BD Biosciences Falcon™; Franklin Lakes, NJ). The well bottoms were covered with polyurethane films composed of cholesterol modified or unmodified polyurethane. Control wells had no polyurethane and presented a tissue culture treated polystyrene surface for attachment. At 15 minute intervals during the 45 minute duration of the study, cells in all treatment groups were washed in phosphate buffered saline and fixed in paraformaldehyde. Cells were stained with a fluorescent, nuclei specific dye (4',6-diamidino-2-phenylindole; DAPI). Cell attachment was determined by counting DAPI labeled cells in 7 random fields using a Nikon (Melville, NY) inverted fluorescent microscope at 20X with the appropriate fluorescent filter set.

As seen in Figure 3, after 30 minutes the average number of cells per field attaching to the cholesterol modified polyurethane was significantly greater than cells seeding onto the unmodified polyurethane surface ($p < 0.05$). This trend continued for the 45 minute duration of the study. During the same time frame, cell attachment to the tissue culture treated plastic and cholesterol modified polyurethane were not significantly different and were virtually identical at the end of the 45 minute duration. These data suggest that cholesterol modified polyurethane is a suitable matrix for the attachment of cardiac myocytes.

The ability of the three matrices to sustain cell survival in culture was assessed by a commercially available LIVE/DEAD® viability/cytotoxicity kit (Molecular Probes; Eugene, OR). This assay distinguishes between viable living cells, indicated by a green fluorescent label, and dead or damaged cells, indicated by a red fluorescent marker. A10 cells grown on tissue culture treated plastic, unmodified polyurethane, or cholesterol modified polyurethane were assessed for viability after seven days in culture. Representative photomicrographs assessing cell viability in A10 cells grown on the indicated substrates for seven days. Cells grown on plastic were about 80% confluent and have a elongated bipolar morphology typical of a smooth muscle cell. There appears to be little or no cell distress as indicated by minimal fluorescent red labeling. In contrast, A10 cells grown for seven days on unmodified

PCT/US2004/021831
Two 2005/007034.1 a more healthy different morphology appearing more cells
grown on plastic. . The extensive red fluorescent labeling and reduced cell number compared to
those cells grown on plastic indicate that this cell culture is clearly distressed and not viable.
Appending cholesterol to the polyurethane maintains the overall morphology of the A10 cells.
5 Analysis of the viability of these cultures show that the culture is rather healthy as indicated by
the widespread green fluorescent labeling and confluence approaching that of cells grown on a
plastic surface. These data show that cholesterol modified polyurethane is superior to
unmodified polyurethane and is equivalent to tissue culture treated plastic in maintaining cell
viability.

10 Endothelial cells serve a vital role in promoting thromboresistance in the
microvasculature. A biocompatible material that is amenable to endothelial cell seeding could
be useful in maintaining a clot free vascular implant. An attachment assay, as detailed above,
examined the affinity of bovine arterial endothelial cells to the cholesterol modified
polyurethane. In addition, substituting serum free media for normal growth media assessed the
15 contribution of exogenous lipids from supplemented serum in the media. The average number of
bovine arterial endothelial cells per field over the 45-minute duration of the experiment is shown
in Figure 5A. After 30 minutes, cell attachment to cholesterol modified polyurethane film was
identical to cell attachment to tissue culture treated plastic. However at the 45-minute timepoint
of the study, cell attachment to modified polyurethane was significantly greater ($p<0.05$) than to
20 plastic. A comparison of cholesterol modified polyurethane to the unmodified control
polyurethane shows that cell attachment to the cholesterol modified polyurethane was more than
twice that to the unmodified polyurethane.

Similar trends were noted in attachment assays performed in serum free media (Figure
5B). After 30 minutes cell attachment to cholesterol modified polyurethane film was greater
25 than to tissue culture treated plastic with significant ($p<0.05$) differences occurring at the 45
minute timepoint of the study. About three times as many cells were attached to the modified
polyurethane than to the unmodified polyurethane after 45 minutes. Comparing cell attachment
to cholesterol modified polyurethane in the presence and absence of serum showed no
differences in values over time strongly suggesting that exogenous lipids in the serum do not
30 influence the attachment of cells to the cholesterol. In addition, these data show that endothelial
cells have a higher affinity to cholesterol modified polyurethane than to tissue culture treated
plastic or unmodified polyurethane.

EXAMPLE IV:

35 Cell Adhesion under Laminar Flow Conditions

The cell attachment properties of polyurethane and cholesterol modified polyurethane

conditions were analyzed. Briefly, BAEC's were grown until confluence on tissue culture treated glass microscope slides or slides coated with Tecothane \pm appended cholesterol, which was generated as described hereinabove. The slides were subsequently attached to a parallel plate laminar flow chamber and media was passed over the cells at 25 dynes/cm² for variable lengths of time. After the indicated times, attached cells were counted using the nuclei specific stain 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI). Cell retention was calculated as a percentage of cells not exposed to shear flow. As seen in Figure 6, tissue culture treated glass and cholesterol modified polyurethane retained 86.76 ± 7.7 and 89.3 ± 13.8 of the original cells after 30 minutes of flow, respectively. After one hour, however, unmodified polyurethane retained only 51.37 ± 11.8 % of the original BAEC population while tissue culture treated glass and cholesterol modified polyurethane retained a similar number of cells as after 30 minutes of laminar flow. After 2 hours of laminar flow, cholesterol modified polyurethane was able to retain significantly more endothelial cells than either polyurethane or tissue culture treated glass (Figure 6). These data show that appending lipids to polyurethane vastly improves the ability of the matrix to retain cells exposed to shear flow.

The foregoing examples demonstrate the lipid derivatized polyurethanes of the instant invention do not induce apoptosis or calcification of cells grown on the matrix. Indeed, cells seeded on lipid derivatized polyurethane attached to the matrix strongly (see Example IV) and thrived as compared to cells grown on other matrices (see, e.g., Figure 5).

A number of literature and patent references are cited in the foregoing application in order to more fully describe the state of the art to which this invention pertains. The disclosure of each of these citations is incorporated by reference herein.

Further provided is a method of treating or preventing a condition in a patient, said method comprising implanting in the patient an implant coated with cells, such that the cells are administered to the patient to treat or prevent the condition, wherein the cells are releasably attached to the implant by a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of a polyurethane component of the implant. Non-limiting examples of condition are thrombosis and inflammatory cell interactions.

The invention will be illustrated in more detail with reference to the following Examples, but it should be understood that the present invention is not deemed to be limited thereto.

EXAMPLE V

WO 2005/007034; PCT/US2004/021831
 Figs. 17A and B demonstrate high shear (2 hour at 25 dyne/cm²) adhesion of cholesterol
 modified but not on unmodified with endothelial precursor cells. In Figs. 18 A and B, a higher
 shear used, 75 dynes/cm² for 2 hours is significant since it is typical heart valve level shear
 force. Also shown are the first results we have demonstrating retention of seeded endothelial
 cells on cholesterol modified polyurethane in blood stream implants.

EXAMPLE VI

Cholesterol modified polyurethane heart valve leaflets were prepared and were
 seeded with endothelial precursor cells. Photomicrographs (see Figures 4A-4D) show
 results before and after 30 day pulmonary valve implantation in sheep demonstrating pre-
 implant confluence (Figure A), and an endothelial monolayer (Figure B), with no
 endothelium developing in unseeded leaflet implants (Figure D); a native heart valve was
 used for comparison (Figure C).

EXAMPLE VII

Table I—Dynamic Mechanical Analyses Results, Cholesterol Modified Tecothane versus
 Unmodified Tecothane with and without Peroxide-Co Oxidative Exposure

	H ₂ O	H ₂ O ₂
Tecothane	-40 °C	-29.78 °C
Tecothane-Cholesterol	-6 °C	-8 °C

Glass transition temperature (T_g) of tecothane configurations exposed to water or oxidative
 degradation (H₂O₂ and CoCl₂) for 14 days at room temperature.

Table II—Contact Angle Results, Cholesterol Modified Tecothane versus Unmodified
 Tecothane with and without Peroxide-Co Oxidative Exposure

<u>Configuration</u>	H ₂ O	H ₂ O ₂
Tecothane	80.61 ± 3.5	68.7 ± 0.03
Tecothane-Cholesterol	98.47 ± 2.37	72.97 ± 6.65

The FTIR curves shown in Figure 15 demonstrate examples of the 1173 peak change
 that occurs during oxidation and is reduced by cholesterol.

The FTIR data from a peroxide-cobalt oxidation study are further summarized as shown in
 Figure 16.

WO 2005/007034. Although the invention has been described in detail and with reference to the preferred embodiment, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

References

- 5 1. Alferiev I, Vyavahare N, Song C, Levy RJ. Elastomeric polyurethanes modified with geminal bisphosphonate groups. *J Polym Sci* 2001;39:105-116.
2. Wisman CB, Pierce WS, Donachy JH, Pae WE, Myers JL, Prophet GA. A polyurethane trileaflet cardiac valve prosthesis: in vitro and in vivo studies. *ASAIO Transactions*. 1982;28:164-8.
- 10 3. Alferiev I, Fishbein I. Activated polyurethane modified with latent thiol groups. *Biomaterials* 2002;23:4753-4758.
4. Alferiev I, Stachelek SJ, Lu Z, Fu AL, Sellaro TL, Connolly JM, Bianco RW, Sacks MS, Levy RJ. Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties. *J Biomed Mater Res* 2003;66A:385-15 95.
5. Stachelek SJ, Song C, Alferiev I, Defelice S, Cui X, Connolly JM, Bianco RW, Levy RJ. Localized gene delivery using antibody tethered adenovirus from polyurethane heart valve cusps and intra-aortic implants. *Gene Ther* 2004;11:15-24.
6. Okano T, Yamada N, Okuhara M, Sakai H, Sakurai Y. Mechanism of cell 20 detachment from temperature-modulated, hydrophilic-hydrophobic polymer surfaces. *Biomaterials* 1995;16:297-303.
7. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. *J. Clin Invest* 2000;105:71-7.
8. Lin Y, Chang L, Solovey A, Healey JF, Lollar P, Hebbel RP. Use of blood outgrowth 25 endothelial cells for gene therapy for hemophilia A. *Blood*. 2002;99:457-62.
9. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. *New Eng J of Med* 1997;337:1584-90.

collagen. J Biomed Mater Res 1994;25:783-9.

11. Frangos J. Shear stress induced stimulation of mammalian cell metabolism. Biotech and Bioeng 1988;32:1053-1060.

12. Yang M, Zhang Z, Hahn C, Laroche G, King MW, Guidon R. Totally Implantable Artificial Hearts and Left Ventricular Assist Devices: Selecting Impermeable Polycarbonate Urethane to Manufacture Ventricles. J Biomed Mat Res 1999;48:13-23.

13. He H, Shirota T, Yasui H, Matsuda T. Canine endothelial progenitor cell-lined hybrid vascular graft with nonthrombogenic potential. J Thorac Cardiovasc Surg 2003;126:455-64.

14. Zhu Y, Gao C, Guan J, Shen J. Engineering porous polyurethane scaffolds by photografting polymerization of methacrylic acid for improved endothelial cell compatibility. J Biomed Mater Res 2003;67A:1367-1373.

15. Zhu Y, Gao C, He T, Shen J. Endothelium regeneration on luminal surface of polyurethane vascular scaffold modified with diamine and covalently grafted with gelatin. Biomaterials 2004;25:423-430.

16. Salacinski HJ, Tai NR, Punshon G, Giudiceandrea A, Hamilton G, Seifalian AM. Optimal endothelialisation of a new compliant poly(carbonate-urea)urethane vascular graft with effect of physiological shear stress. Eur J Vasc Endovasc Surg 2000;20:342-52.

17. Salacinski HJ, Punshon G, Krijgsman B, Hamilton G, Seifalian AM. A hybrid compliant vascular graft seeded with microvascular endothelial cells extracted from human omentum. Art Org 2001;25:974-82.

18. Krijgsman B, Seifalian AM, Salacinski HJ, Tai NR, Punshon G, Fuller BJ, Hamilton G. An assessment of covalent grafting of RGD peptides to the surface of a compliant poly(carbonate-urea)urethane vascular conduit versus conventional biological

19. Tiwari A, Salacinski HJ, Punshon G, Hamilton G, Seifalian AM. Development of a hybrid cardiovascular graft using a tissue engineering approach. FASEB Journal 2002;16:791-6.
- 5 20. Hsu S-h, Sun S-h, Chen D. Improved Retention of Endothelial Cells Seeded on Polyurethane Small-diameter Vascular Grafts Modified by a Recombinant RGD-containing Protein. Art Org 2003;27:1068-1078.
21. Deutsch M, Meinhart J, Fischlein T, Preiss P, Zilla P. Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience. Surg 1999;126:847-55.
- 10 22. Laube HR, Duwe J, Rutsch W, Konertz W. Clinical Experience With Autologous Endothelial Cell-Seeded Polytetrafluoroethylene Coronary Artery Bypass Grafts. J Thorac Cardiovasc Surg 2000;120:134-41.
23. Shirota T, He H, Yasui H, Matsuda T. Human endothelial progenitor cell-seeded hybrid graft: proliferative and antithrombogenic potentials in vitro and fabrication processing. Tis Eng 2003;9:127-36.
- 15 24. Kaushal S, Amiel GE, Guleserian KJ, Shapira OM, Perry T, Sutherland FW, Rabkin E, Moran AM, Schoen FJ, Atala A and others. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo.[see comment]. Nat Med 2001;7:1035-40.
- 20 25. Dvorin EL, Wylie-Sears J, Kaushal S, Martin DP, Bischoff J. Quantitative evaluation of endothelial progenitors and cardiac valve endothelial cells: proliferation and differentiation on poly-glycolic acid/poly-4-hydroxybutyrate scaffold in response to vascular endothelial growth factor and transforming growth factor beta1. Tis Eng 25 2003;9:487-93.
26. Li YJ, Shibata Y, Nakaya T. Synthesis and characterization of polyurethanes containing cholesterol and phosphatidylcholine analogous moieties. Macromol Rap

27. Li YJ, Yokawa T, Matthews KH, Chen TM, Wang YF, Kodama M, Nakaya T.
Synthesis and blood compatibility evaluation of segmented polyurethanes based on
cholesterol and phosphatidylcholine analogous moieties. Biomaterials 1996;17:2179-
89.
28. Kim JH, Kim SH, Kim HK, Akaike T, Kim SC. Adhesion and growth of endothelial
cell on amphiphilic PU/PS IPN surface: effect of amphiphilic balance and
immobilized collagen. J Biomed Mater Res 2002;62:613-621.

WHAT IS CLAIMED IS:

5 1. A modified polyurethane comprising a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane.

 2. The modified polyurethane of claim 1, wherein the lipid substituent is a steroid lipid substituent.

10 3. The modified polyurethane of claim 1, wherein the steroid lipid substituent is a member selected from the group consisting of a thiol-modified cholesterol substituent, an amino-modified cholesterol substituent, a carboxy-modified cholesterol substituent, and an epoxy-modified cholesterol substituent.

 4. The modified polyurethane of claim 3, wherein the thiol-modified cholesterol substituent is a 3-mercapto-2-hydroxypropyl-cholesterol.

15 5. The modified polyurethane of claim 2, further comprising a linker moiety between (1) the steroid lipid substituent and (2) the at least one urethane nitrogen and/or the at least one carbon atom of the modified polyurethane, wherein the linker moiety covalently binds the steroid lipid substituent with the at least one urethane nitrogen and/or the at least one carbon atom.


20 6. The modified polyurethane of claim 5, wherein the linker moiety is an (n+1)-valent organic radical comprising at least one carbon atom.

 7. The modified polyurethane of claim 6, wherein the linker moiety is a bivalent organic radical selected from the group consisting of C₁ to C₁₈ alkylene, C₁ to C₁₈ alkyleneamino, C₁ to C₁₈ alkyleneoxy, C₁ to C₁₈ haloalkylene, C₂ to C₁₈ alkenylene, C₆ to C₁₈ arylene, a modified C₂ to C₁₈ alkenylene having at least one carbon substituted by a halogen group, C₂ to C₁₈ alkenylene having one or more O, S, or N atoms incorporated into an alkenylene chain, a bivalent heterocyclic radical, and mixtures thereof.

 8. The modified polyurethane of claim 7, wherein the linker moiety is C₁ to C₆ alkylene.

30 9. The modified polyurethane of claim 8, wherein the linker moiety is butylene.

 10. The modified polyurethane of claim 1, wherein the lipid substituent is a thiol-modified cholesterol substituent bound to the at least one urethane nitrogen and wherein said modified polyurethane has a formula:



11. The modified polyurethane of claim 1, wherein the lipid substituent is pendant from about 0.5 to about 50% of urethane nitrogen atoms and/or about 0.5 to about 50% of carbon atoms.

12. The modified polyurethane of claim 11, wherein the lipid substituent is pendant from 1 to 20% of urethane nitrogen atoms and/or 1 to 20% of carbon atoms.

13. The modified polyurethane of claim 12, wherein the lipid substituent is pendant from 5 to 10% of urethane nitrogen atoms and/or 5 to 10% of carbon atoms.

14. The modified polyurethane of claim 1, wherein the modified polyurethane comprises at least about 10 micromoles of the lipid substituent per gram of the modified polyurethane.


15. The modified polyurethane of claim 1, wherein the modified polyurethane has at least two different lipid substituents pendant from urethane nitrogen atoms and/or carbon atoms.

16. The modified polyurethane of claim 1, wherein said modified polyurethane is less prone to degradative oxidation than a polyurethane.

17. A process for preparing the modified polyurethane of claim 1, the process comprising:

providing a polyurethane comprising a urethane amino moiety and at least one carbon;

providing a multifunctional linker reagent of a formula:



wherein n is an integer from 1 to 3, FG is a functional group selected from the group consisting of a halogen, a carboxyl group, a sulfonate ester, and an epoxy group, LG is a leaving group selected from the group consisting of a halogen, a carboxyl group, a sulfonate ester, and an epoxy group, and R_L is an $(n+1)$ -valent organic radical comprising at least one carbon atom;

providing a lipid comprising the lipid substituent;

reacting the multifunctional linker reagent with the urethane amino moiety to form a polyurethane substituted with at least one substituent group of a formula

reacting the lipid and the polyurethane substituted with the at least one substituent group to form the modified polyurethane.

18. The process of claim 17, wherein R_L is a bivalent organic radical selected from the group consisting of C_1 to C_{18} alkylene, C_1 to C_{18} alkyleneamino, C_1 to C_{18} alkyleneoxy, C_1 to C_{18} haloalkylene, C_2 to C_{18} alkenylene, C_6 to C_{18} arylene, a modified C_2 to C_{18} alkenylene having at least one carbon substituted by a halogen group, C_2 to C_{18} alkenylene having one or more O, S, or N atoms incorporated into an alkenylene chain, a bivalent heterocyclic radical, and mixtures thereof.

19. The process of claim 18, wherein the multifunctional linker reagent is a member selected from the group consisting of a dibromoalkyl compound, a bromo-carboxyalkyl compound, and a bromo-epoxyalkyl compound.

20. The process of claim 17, wherein the lipid comprises a steroid lipid and the lipid substituent comprises a steroid lipid substituent.

21. The process of claim 20, wherein the steroid lipid comprises modified cholesterol and the steroid lipid substituent is a member selected from the group consisting of a thiol-modified cholesterol substituent, an amino-modified cholesterol substituent, a carboxy-modified cholesterol substituent, and an epoxy-modified cholesterol substituent.

22. The process of claim 21, wherein the modified cholesterol comprises 3-mercapto-2-hydroxypropyl-cholesterol.

23. The method of claim 21, comprising preparing the modified cholesterol by contacting a cholesterol with at least one reactant to provide the modified cholesterol having at least one substituent group, wherein the substituent group is a member selected from the group consisting of a thiol group, an amino group, a carboxy group, and an epoxy group.

24. The method of claim 23, wherein the cholesterol is treated with epihalohydrin to yield a glycidyl modified cholesterol and the glycidyl modified cholesterol is treated with a thiolating agent to yield a thiol modified cholesterol.

25. A process for preparing the modified polyurethane of claim 1, the process comprising:

reacting a steroid lipid with epihalohydrin to yield a glycidyl derivative of the steroid lipid;

reacting the glycidyl derivative of the steroid lipid with a thiolating agent, thereby effecting opening of the glycidyl oxirane group and adding to said lipid molecule a thiol moiety having a protective group bound thereto;

removing said protecting group to produce a thiol-substituted steroid lipid;

reacting a polyurethane with a bi-functional linker comprising a thiol-reactive group, to

WO 2005/007034 PCT/US2004/021831
yield an intermediate polyurethane having a thiol-reactive functional group wherein the
thiol-reactive functional group is substituted on said urethane group nitrogen;

reacting the thiol-substituted steroid lipid with the intermediate polyurethane having a
thiol-reactive functional group to yield the modified polyurethane.

5 26. The process of claim 25, wherein the epihalohydrin is epibromohydrin.

27. The process of claim 25, wherein the thiolating agent is selected from the group
consisting of thiosulfate, thiourea, trityl-butylmercaptanes, tert-butylmercaptanes, thiocyanate,
and thioalkanoic acids having 2 - 6 carbon atoms.

28. The process of claim 27, wherein the thiolating agent is thioacetic acid.

10 29. The process of claim 25, wherein the bi-functional linker is a dihaloalkane having
1-12 carbon atoms.

30. The process of claim 29, wherein the bi-functional linker is 1,4-dibromobutane.

31. A process of producing an implant, said process comprising:

15 providing the modified polyurethane of claim 1,
forming an article from the modified polyurethane;

contacting the article with cells to attach the cells to the lipid substituent and thereby
attach the cells to the article to form the implant, provided that a substantial portion of the cells
remains attached to the implant when exposed to a fluid-induced sheer stress.

20 32. The process of claim 31, wherein the lipid substituent is a member selected from
the group consisting of a thiol-modified cholesterol substituent, an amino-modified cholesterol
substituent, a carboxy-modified cholesterol substituent, and an epoxy-modified cholesterol
substituent.

33. The process of claim 31, wherein the cells are endothelial cells or precursors of
endothelial cells.

25 34. The process of claim 33, wherein the endothelial cells are bovine arterial
endothelial cells or blood outgrowth endothelial cells.

35. An implant produced by the process of claim 31.

30 36. The implant of claim 35, wherein the implant is a member selected from the
group consisting of an artificial heart; cardiac pacer leads; automatic implantable
cardio defibrillator leads; a prosthetic heart valve; a cardiopulmonary bypass membrane; a
ventricular assist device; an annuloplasty ring; a dermal graft; a vascular graft; a vascular stent;
cardiovascular stent; a structural stent; a catheter; a guide wire; a vascular shunt; a
cardiovascular shunt; a dura mater graft; a cartilage graft; a cartilage implant; a pericardium
graft; a ligament prosthesis; a tendon prosthesis; a urinary bladder prosthesis; a pledget; a
35 suture; a permanently in-dwelling percutaneous device; an artificial joint; an artificial limb; a
bionic construct; and a surgical patch.

WO 2005/007034 the implant of claim 35, wherein the cells are blood outgrowth endothelial cells. PCT/US2004/021831


38. A method of treating a patient comprising providing the implant of claim 35, wherein the implant is seeded with blood outgrowth endothelial cells.

39. A method of treating or preventing a condition in a patient, said method comprising implanting in the patient an implant coated with cells, such that the cells are administered to the patient to treat or prevent the condition, wherein the cells are releasably attached to the implant by a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of a polyurethane component of the implant.

40. The method of claim 39, wherein the condition is at least one of thrombosis and inflammatory cell interactions.


1/19

Figure 1




2/19

Figure 2



3/19

Figure 3



4/19

Figure 4A




Figure 4B




Figure 4C





Figure 4D



5/19

Figure 5A






Figure 5B




6/19

Figure 6**BAEC attachment to substrate
(25 dynes/cm²)**


7/19

Figure 7



R = polyurethane macromolecule, Su = N-succinimidyl, DCC = dicyclohexylcarbodiimide,


8/19
Figure 8




A = p-C₆H₄CH₂C₆H₄-p (polyurethanes based on MDI) or
 cyclo-C₆H₁₀CH₂C₆H₁₀-cyclo (aliphatic polyurethanes based on HMDI)
 X = residue of polytetramethyleneoxide (polyether-urethanes) or
 polycarbonatediol (polycarbonate-urethanes)

9/19

Figure 9



10/19
Figure 10



11/19
Figure 11A





Figure 11B



12/19

Figure 12A






Figure 12B




13/19

Figures 13A-L




14/19

Figure 13M




15/19
Figures 14A-L



16/19

Figure 14M



17/19
Figure 15

FSD Tec in d₄H₂O 1
FSD Tec in H₂O₂/CoCl₂ 1
FSD Tec-choi in d₄H₂O 1
FSD Tec-choi in H₂O₂/CoCl₂ 1





Figure 16

Oxidative Degradation of Tecothane



18/19

Figure 17A





Figure 17B



19/19

Figure 18A





Figure 18B



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/21831

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61F 2/04, 2/06, 2/10, 2/24; C08F 283/04

US CL : 525/453; 623/1.49, 2.42, 23.64, 23.76

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 525/453; 623/1.49, 2.42, 23.64, 23.76

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,745,136A (THOMAS et al) 17 May 1988 17.05.1988), examples.	1-40
A	US 5,624,975A (VALENCIA) 29 April 1997 (29.04.1997), claim 3.	1-40
A	US5,403,750A (BRAATZ et al) 04 April 1995 (04.04.1995), example IX.	1-40

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

12 November 2004 (12.11.2004)

Date of mailing of the international search report

03 JAN 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Rachel F. Gorr

Telephone No. 571-272-1700

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ ~~FADED TEXT OR DRAWING~~
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ ~~SKewed/SLANTED IMAGES~~
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.